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Ubiquitination, also known as ubiquitylation, is a major type of post-translational 
modification (PTM), which is closely associated with numerous cellular processes, such 
as protein degradation, intracellular trafficking, cell signaling, and DNA damage 
response. Substrate proteins can be monoubiquitinated at one or multiple lysine residues 
or further polyubiquitinated at one of the eight possible sites (seven lysines and N-
terminal methionine) of ubiquitin (Ub) itself. Thus, various ubiquitin polymers (poly-Ub) 
with distinct linkage types will be produced and they possess different topological 
characteristics and cellular functions. Deubiquitinases (DUBs), also called 
deubiquitinating enzymes, can remove Ub from target proteins and regulate most Ub-
dependent processes. The human genome encodes ~100 DUBs, which are essential for 
ubiquitin homeostasis, protein stability, and a wide range of signaling pathways. 
Consistent with this, their misregulations have been implicated in the pathogenesis of 
many human diseases, including chronic inflammatory diseases and various types of 
cancer. In contrast to the increasing interest in deubiquitinases study, ubiquitin 
conjugates that allow quantitative analyses of DUB activities and high-throughput 
screening (HTS) of DUB inhibitors, as well as poly-Ub with various linkage types for 
DUB structural and functional studies are not readily accessible.  
A straightforward and readily adoptable approach that employed ubiquitin-
activating enzyme (E1)-catalyzed amidation reaction to append ubiquitin C-terminus 




well as poly-Ub mimics with high efficiency was developed. With this facile method, 
Ub-based fluorescent substrates with distinct flexible linkages, which could mimic the 
native isopeptide bond in physiological DUB substrates, were produced and tested with 
one common DUB, UCH-L3 (ubiquitin carboxyl-terminal hydrolase isozyme L3). 
Moreover, desirable poly-Ub with diverse linkage types could also be readily generated, 
in combination with thiol-ene coupling (TEC) chemistry, thereby providing abundant 
versatile substrates for DUB specificity study. A novel luminescence-based experiment 
for high-throughput screening (HTS) was also developed and applied to the discovery of 
ubiquitin specific peptidase 2 (USP2) inhibitors for cancer therapy. Altogether, these 
novel chemical biology tools allow accelerated studies of DUBs that have pivotal roles 
in numerous cellular pathways, but whose investigations have been hampered by the 
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CHAPTER I  
INTRODUCTION  
 
Protein Post-Translational Modifications 
In eukaryotes, the diversity and complexity of the proteome (>1,000,000 
molecular species of proteins) is achieved by two major routes that greatly expand the 
number of proteins predicted by DNA coding capacities (30,000 human genes) to two to 
three orders of magnitude, namely mRNA splicing at the transcriptional level and 
covalent post-translational modifications (PTMs) of proteins at one or more sites at the 
translational level.1 PTM occurs after mRNA has been translated into proteins, 
especially after release of polypeptides from ribosome during the biosynthesis of 
proteins, and refers to a series of chemical reactions catalyzed by specific enzymes 
whereby the side chain or backbone of a ribosomally coded amino acid residue is 
converted into a non-standard amino acid residue.2 For example, protein splicing, green 
fluorescent protein (GFP) maturation and proteasome autoactivations are representative 
PTM processes.1 It is well known that 20 amino acids are the building blocks of proteins, 
and 15 of them contain side chains that can undergo covalent additions to constitute 
more than 100 different enzymatically modified amino acid residues found in various 
proteins.3 Prominent posttranslational modifications include (a) phosphorylation of 
serine, threonine, tyrosine, histidine, aspartic acid, arginine, and lysine; (b) lysine 
acetylation; (c) tyrosine sulfation; (d) lysine, arginine and proline methylation; (e) lysine 




PTMs have already been illustrated and discovery of new ones is still one of the most 
active fields of research currently.1-4 
These major and minor categories of post-translational modifications lead to 
tremendous diversity, complexity and heterogeneity of gene products and generate 
millions of possible molecular variants of proteins in eukaryotic cells. Far from being 
"decorations", PTMs can grant proteins with expanded opportunities for catalysis, 
regulating signal transduction, controlling gene expression, integration of information at 
many metabolic intersections, and alternation of cellular locations. Thus, they are 
fundamental to cellular signaling, growth and transformation. For example, in signaling, 
kinase cascades are turned on and off by the reversible addition and removal of 
phosphate groups, and in the cell cycle ubiquitination marks cyclins for destruction at 
defined time points. Failure to control complex PTM processes is detrimental to the 
survival of the cell and a range of post-translationally modified proteins and their 
substrates are implicated in human diseases, including cancers, diabetes, and numerous 
neurological disorders.5-7 
Protein Ubiquitination Process 
The diversity and functional breadth of an organism’s proteome are significantly 
more complex than genome and transcriptome due to extensive PTMs of proteins.1,3 
Hundreds of different modifications exist, including modifications by small molecules 
such as phosphate, methyl, or acetyl groups and by small proteins such as ubiquitin (Ub) 
and ubiquitin-like (Ubl) proteins that can be attached covalently to protein substrates.2 




76-residue polypeptide that is ubiquitously expressed and highly conserved among 
eukaryotic organisms but is absent from bacteria and archaea.1,8,9 
Ubiquitin was first discovered in the mid-1970s, and its most widely understood 
function is to tag intracellular proteins for proteasomal degradation.10 The 2004 Nobel 
Prize in Chemistry was awarded to Avram Hershko, Aaron Ciechanover and Irwin Rose 
for this finding.11 Ubiquitin is a highly stable protein that adopts a compact β-grasp fold 
with a flexible six-residue C-terminal tail (Figure 1A).10 With three conservative 
changes, ubiquitin is almost invariant from yeast to plants and mammals. This strong 
sequence conservation suggests high evolutionary pressure to conserve the structure of 
ubiquitin and that ubiquitin plays a fundamental role in maintaining cell function and in 
species evolution.12,13 Actually, ubiquitin is involved in almost all aspects of cellular 
activities by regulating its extensively targeted proteins via ubiquitination (also called 
ubiquitylation), one of the most common and important protein post-translational 
modifications.14,15 
Ubiquitination is an ATP-dependent biological process where a single Ub moiety 
is covalently tagged to target proteins via an amide bond between the Ub C-terminal di-
glycine motif and ε-amino group in a lysine (K) residue, or less frequently, the free 
amino-terminus of target proteins.10,11 The attachment of ubiquitin molecules to their 
targets is carried out by the sequential actions of a cascade of enzymes including 
ubiquitin-activating enzymes (E1s),16,17 ubiquitin conjugating enzymes (E2s),18 and 









Figure 1. (A) The structure of ubiquitin. Seven lysines, the first methionine and the C-
terminal carboxylate group are labeled.10 (B) Scheme of protein ubiquitination process, 





In the process of ubiquitination, initially, the C-terminal glycine (Gly76) of Ub is 
activated by the E1 enzyme using ATP as an energy source to adenylate Ub at its C 
terminus, forming a ubiquitin-adenylate intermediate. Subsequently, the high-energy 
mixed anhydride bond is quickly attacked by the sulfhydryl group of the active-site 
cysteine in E1 enzyme, forming a high-energy thioester bond between the E1 and the C 
terminal carboxyl group of ubiquitin.20-22 Secondly, the activated ubiquitin is passed 
from E1 to the active-site cysteine residue of E2 enzyme via a trans(thio)esterification 
reaction, and a novel thioester is formed. Finally, Ub is conjugated to its substrate, 
creating an isopeptide/peptide bond between a carboxyl group at the C-terminus of 
ubiquitin and an amino group in the substrate with the aid of an E3 ligase enzyme, which 
identifies specific recognition modules in the target proteins and is capable of 
interactions with both E2 enzymes and target proteins.23,24 
Theoretically, any lysine residues in a protein can be targeted by ubiquitination 
process, including ubiquitin itself. There are seven lysine residues (K6, K11, K27, K29, 
K33, K48, and K63) among the 76 amino acids of ubiquitin (Figure 1A), as well as the 
N-terminal amino group of methionine, which can themselves be targeted for 
ubiquitination to generate polyubiquitin (poly-Ub) chains of different linkage types 
depending on which amino group acts as the acceptor site for the incoming ubiquitin 
(Figure 2A).25,26 In particular, the C terminus of the more distal ubiquitin molecule is 
attached to the previous ubiquitin molecule through an isopeptide bond with an ε-amino 
group of a Ub lysine. The last ubiquitin moiety in a poly-ubiquitin chain without a 




into three groups based on the number of tagged ubiquitins: i) monoubiquitination: 
proteins are modified by a single ubiquitin, such as Lys164 in proliferating cell nuclear 
antigen (PCNA);27,28 ii) multi-monoubiquitination: proteins are tagged with several 
single ubiquitin molecules at multiple sites, with the epidermal growth factor receptor 
(EGFR) as an example; iii) polyubiquitination: proteins are attached with chains of 
ubiquitin molecules. These polyubiquitin chains can be as short as only two ubiquitin 
molecules or as long as more than ten moieties (up to 20).1,10,27,29-33 Moreover, these 
chains can be homogenous if the same residue is modified during elongation, or mixed if 
different linkages alternate at succeeding positions of the chain, or branched when a 
single ubiquitin is modified at multiple lysine sites (Figure 2), and all possible linkages 
mentioned above have been detected in cells, but only Lys48- and Lys63-linked chains 




Figure 2 (A) The isopeptide and peptide linkages between two Ubs, (B) the homo- and 





Considering seven internal lysine residues and one N-terminus amino group in 
ubiquitin, there are eight possible positions for the second ubiquitin to attach, while for 
the third ubiquitin, there are 15 possible positions of attachment, thus, with chains of 
varying lengths and types, the structures of polyubiquitin chains in cells can be 
remarkably diverse, which has a profound impact on the fate of the modified 
proteins.10,11,35 The syntheses of specific linked polyubiquitin chains are guaranteed in a 
sophisticated and economic way via the E1-E2-E3 cascade. In the human genome, there 
are two genes encoding different isoforms of E1 enzymes and each form has a distinct 
preference for E2s. There are at least 37 genes that encode distinctive E2s.18 The number 
of the genes encoding E3s is over one thousand, which approximately equals the number 
of genes encoding kinases, underlining the universal significance of ubiquitination.19 In 
this ubiquitination cascade, E1 can bind to dozens of E2s, which can bind to hundreds of 
E3s, and E3s specifically target thousands of substrate proteins. Numerous E2s and E3s 
and the combinatorial possibilities of various E2s and E3s provide the molecular basis 
for the stringent substrate specificity of polyubiquitination, thus, for any target substrate, 
there are two decisions for a specific E2/E3 pair to make: which substrate residue to 
modify and which Ub linkage to use for chain assembly. Therefore, this E1-E2-E3 
cascade forms a hierarchical structure to control the whole ubiquitination process.11,24  
Attachment of a Ub or Ub chain to a protein changes the protein surface 
topography in the conjugate substantially compared to that of the unmodified protein, 
resulting in either enhanced or inhibited binding capacity of the target protein to another 




tagged proteins.24,25,29 Because myriad proteins can be ubiquitinated, ubiquitination has 
emerged as one of the most important PTMs in regulation of protein function. Various 
ubiquitin modifications adopt distinct conformations and provide an information-rich 
architectural scaffold with key roles in nearly all the important cell biological activities, 
including protein degradation, cell metabolism, signal transduction, membrane traffic, 
transcriptional regulation, endocytosis, DNA repair, chromatin remodeling, peroxisome 
biogenesis and viral budding.2,31,33 The functional consequences of ubiquitination are 
gradually being deciphered, and the number of biological pathways known to be 
regulated by ubiquitination continues to grow. Not surprisingly, abnormalities in 
ubiquitin-mediated processes are causally linked to pathologies, including inflammation, 
arthritis, heart disease and cancers.9,10,27,28  
The most well-established physiological role for ubiquitination is to target 
proteins for degradation by the proteasome.28 For this purpose, ubiquitin is attached to 
the substrate in the form of a polyubiquitin chain that can be recognized by specific 
receptors within the proteasome, and subsequently removed hydrolytically during ATP-
driven unfolding of the targeted protein.11 The unfolded protein is then threaded into the 
chamber of the proteasome where the active sites of the protease subunits degrade it into 
small peptides.36 The “classical” signal for protein degradation is the Lys48-linked 
polyubiquitin chain of at least four ubiquitin moieties to the target protein, which 
constitutes an architectural for efficiently binding to the proteasome and for degradation. 
Lys11-, Lys29-, Lys48-, and Lys63-linked chains might all have roles in proteasomal 




than other modifications, which is possibly due to the fact that enzymes synthesizing 
Lys11- and Lys48-linked chains are less likely to introduce branches, which can impede 
degradation.8,13,36-38 
Although mostly associated with proteasomal degradation, ubiquitination is also 
involved in regulatory events in a proteasome-independent manner, mostly resulting 
from monoubiquitination or Lys63-linked chain formation.39 Protein monoubiquitination 
plays essential roles in endocytosis and transcriptional regulation processes, and is a tool 
for the reversible recruitment of an enzyme to a particular cellular location, which can 
initiate relocation of transmembrane receptor proteins from the plasma membrane to the 
trans Golgi network sorting compartments.1,40 While the Lys63-linked 
polyubiquitination is mainly responsible for modifications of protein functions and 
related to a variety of different cellular pathways like endocytosis of cell surface 
receptors, cell signaling, mitochondrial inheritance and morphogenesis, ribosomal 
function, DNA repair and activation of the NFκB (nuclear factor kappa-light-chain-
enhancer of activated B cells) signaling complex.33,41 
Following the discovery of ubiquitin in the mid-1970s, a number of distinct small 
proteins called ubiquitin-like (Ubl) proteins have been uncovered to function as protein 
modifiers as well, and new members are still being added.42 These Ubl proteins, which 
include SUMO, ISG15, Nedd8, Atg8, FUBI, HUB1, FAT10, URM1, UFM1 and Atg12, 
function as critical regulators of many cellular processes, such as transcription, DNA 




modification and mutations in the Ubl conjugation machinery are implicated in the 
etiology and progression of a number of human diseases.8,37 
Despite limited sequence homology of some Ubl proteins with ubiquitin, all Ubl 
proteins display structural homology with essentially the same characteristic β-grasp 
ubiquitin fold. Furthermore, for all Ubl proteins whose covalent attachments to proteins 
have been experimentally demonstrated, the C-terminal residue of the Ubl is a glycine, 
and the carboxyl group of this glycine is the site of attachment to substrates. The ε-
amino groups of lysine side chains are the most common target sites within substrate 
proteins, forming an isopeptide bond between the Ubl and substrate.17,40,43 Among them, 
small ubiquitin-like modifier (SUMO) is the most studied one and affects a similar large 
number of substrates as ubiquitin. However, the pathway of SUMOylation is much 
simpler with only one E1 (Uba2/Aos1), one E2 (Ubc9), and a few E3 ligases. Generally, 
Ubc9 binds substrates directly, while E3 ligases can also contribute to substrates 
specificity. Both ubiquitin and SUMO can form poly-modifier chains conjugated to 
lysine residues in substrates. Recently, it was discovered that SUMO itself may be 
modified by ubiquitin, resulting in mixed ubiquitin/SUMO chains.44,45 Still, much more 
needs to be uncovered in the research fields of ubiquitin and Ubl proteins. 
Deubiquitinases (DUBs) 
Similar to other post-translational modifications, such as phosphorylation and 
acetylation, ubiquitination process is highly dynamic and can be reversed by a large and 
growing group of proteases, termed deubiquitinating enzymes (DUBs; also known as 




specifically cleaving the isopeptide bond between the ε-amino group of lysine side chain 
in the target protein and the C-terminal carboxyl group of ubiquitin, or the peptide bond 
between the N-terminal amino group of the target protein and the C-terminal carboxyl 
group of ubiquitin.11,12 DUBs oppose the actions of the E3 ligases, thus, it is the delicate 
balance between the actions of specific E3 ligases and DUBs which ultimately determine 
the ubiquitination status of a given target protein, resulting in DUBs acting as pivotal 
regulators of ubiquitin mediated signaling pathways.46-49  
Analysis of the human genome shows the presence of at least 98 functional 
DUBs, which can be grouped into six families based on structural homology:  ubiquitin-
specific proteases (USPs), ubiquitin C-terminal hydrolases (UCHs), ovarian-tumor 
proteases (OTUs), Machado–Joseph disease protein domain proteases, JAMM/MPN 
domain-associated metallopeptidases (JAMMs) and the recently discovered monocyte 
chemotactic protein-induced proteins (MCPIPs).15 All of them are cysteine (Cys) 
proteases with the exception of JAMMs, which are zinc metalloproteases. The reaction 
mechanism of Cys proteases DUB families (USPs, UCHs, OTUs, Josephins and 
MCPIPs) rely on two or three crucial amino acid residues, constituting a catalytic dyad 
or triad, respectively.50 In these enzymes, a nearby histidine (His) side chain lowers the 
pKa of a catalytic Cys, enabling a nucleophilic attack on isopeptide linkages so that the 
carboxyl group is covalently bound to the catalytic Cys after the amino group has been 
cleaved. A third residue (usually asparagine (Asn) or aspartic acid (Asp)) aligns and 
polarizes the catalytic His. In a second step, a water molecule hydrolyses the acyl-Cys 




folds, the catalytic residues of all Cys protease DUB families superpose with only small 
deviations when bound to the ubiquitin C-terminus.51,52 For JAMM DUBs, the 
JAMM/MPN+ motif coordinates two zinc ions, one of which activates a water molecule 
to attack the isopeptide bond. The amino group is subsequently released from the 
charged catalytic intermediate.15 The activity of these enzymes affects the activation, 
recycling and localization of multiple proteins, which in turn is essential for cell 
homeostasis, protein stability and a wide range of signaling pathways, therefore, much 
progress has been made in the characterization of DUBs recently.53,54 
USP constitutes the largest DUB family with more than 60 members, which 
makes up about half of all DUBs. Structures of the catalytic domains of several USPs 
have been determined, revealing that the USP fold is highly conserved and consists of 
three subdomains resembling the palm, thumb and fingers of a right hand, despite of 
limited sequence homology. The catalytic cysteine and histidine residues (Cys-box and 
His-box) are located in the cleft separating the palm and thumb, whereas the finger 
domain is responsible for interactions with distal ubiquitin, with the only exception of 
CYLD (cylindromatosis D) which lacks the finger domain. Furthermore, most USPs 
share the common feature of undergoing conformational changes upon ubiquitin binding, 
which drives the transition from an inactive form to a catalytically active state. This is 
well characterized for USP7, for which ubiquitin binding is required to induce changes 





UCH is the first DUB family to be structurally characterized and is composed of 
four members in human cells: UCH-L1 (ubiquitin C-terminal hydrolase isozyme L1), 
UCH-L3, UCH-L5/UCH37 and BAP1 (BRCA1 Associated Protein-1). These enzymes 
are small in size and they have a confined loop preventing binding of large, fully folded 
ubiquitin conjugates and precluding the processing of polyubiquitin chains and large 
folded proteins, which is consistent with the failure to observe UCH-L1 or UCH-L3 
mediated hydrolysis of tetra-ubiquitin chains.51,57 Therefore, they can merely target 
small peptide conjugates from the C-terminus of ubiquitin, which may be produced as 
by-products of proteasomal or lysosomal degradation.  
The OTU domain was first identified in an ovarian tumor gene from Drosophila 
melanogaster by a bioinformatics approach. So far, 15 protein-coding genes with OTU 
domains have been discovered in the human genome, which can be classified in 3 groups: 
otubains (OTUB1 and OTUB2), A20-like OTUs (A20/TNFAIP3; Cezanne, Cezanne 2, 
TRABID and VCPIP1) and OTUDs (OTUD1, OTUD2/YOD1, OTUD3, OTUD4, 
OTUD5, OTUD6A, OTUD6B and ALG13). The OTU core domain is composed of five 
β-strands, situated between helical domains that vary in size among OTU family 
members. Also, the OTU core is accompanied by ancillary ubiquitin-binding domains 
such as A20-type Zn fingers in A20, NPL4-type Zn fingers in TRABID, ubiquitin-
interacting motif in OTUD1 and OTUD5, as well as ubiquitin-associated domain in 
Cezanne.52,58-60 
The Josephin family of DUBs is composed of four different members including 




studied member, which contains a poly-glutamine (poly-Gln) stretch whose extension 
leads to the neurodegenerative disorder Machado-Joseph disease (MJD). All four 
members contain the highly conserved catalytic triad consisted of one cysteine and two 
histidine residues. Apart from the Josephin domain, ATXN3 and ATXN3L have 
additional domains like ubiquitin-interacting motif (UIM), suggesting a possible 
interaction with two distal ubiquitins in a polymer.15,61,62 
The JAMM forms the only family of DUBs with metalloprotease activity, and 
human genome encodes 12 JAMM proteins, 5 of which are catalytically inactive, 
whereas the rest of them have isopeptidase activity for ubiquitin or ubiquitin-like 
proteins (Ubl): AMSH-LP, AMSH/STAMBP, BRCC36 (BRCA1/BRCA2-containing 
complex subunit 36), POH1/PSMD14 (26S proteasome-associated PAD1 homolog 1), 
MYSM1 (Myb-like with SWIRM and MPN domains 1), MPND (MPN domain-
containing protein) and CSN5/JAB1 (COP9 signalosome subunit 5). The members of the 
AMSH subfamily (POH1, AMSH and AMSH-LP) share high degree of sequence 
conservation with composition of a JAMM core and two conserved insertions which 
contributes to its specific recognition and DUB catalysis of Lys63-linked polyubiquitin 
chains, while other JAMM proteases with no specificity for Lys63-linked polyubiquitin 
chains lack the AMSH-specific insertions.52,63 
Recently, DUB families have expanded due to the discovery of a novel domain 
exhibiting deubiquitinating activity in the MCPIP1 protein. According to a 
bioinformatics analysis, the sixth DUB family should be composed of at least seven 




MCPIP6, and MCPIP7). The founding member MCPIP1 contains an N-terminal 
conserved region and a conserved CCCH-type zinc-finger domain in the middle region 
of the protein which are critical for its activity. Besides, its catalytic domain contains the 
Cys and Asp boxes consistent with characteristics of cysteine proteases, but lacks the 
conserved His box.15,64 
The existence of six families of nearly 100 DUBs reflects the need for specificity 
in their functions. The small number (<100) of DUBs, compared to thousands of E3s, 
might at first imply a low degree of selectivity; however, DUBs can display specificity at 
multiple levels to distinguish between different types of ubiquitin linkage and chain 
structure. Currently, owing to the unavailability of well-defined ubiquitin chain 
preparations, other than linear, Lys48- or Lys63-linked chains, we still don’t have a 
complete picture of DUB specificity. Once appropriate reagents are available, it is 
mostly likely that new DUB families will be discovered due to the existence of highly 
specific DUBs.65 
First of all, each Lys in ubiquitin has a unique sequence context and can 
construct eight topologically different ubiquitin chains, which allows for specific 
recognition by the DUBs. Strikingly, the ability of DUBs to discriminate distinct chain 
linkages is not restricted to particular DUB families: the USPs, OTUs, and JAMMs all 
include linkage-specific members.15 For example, the 26S proteasome-associated USP14 
shows specificity for Lys48-linked ubiquitin chains, whereas JAMM family DUBs are 
often Lys63 linkage specific, as seen for AMSH, AMSHLP, BRCC36, and POH1.66,67 In 




specific for Lys48 linkage, Cezanne is specific for Lys11 linkages, and TRABID is 
specific for Lys29 and Lys33 linkages.68,69 Besides, polyubiquitin chains can be cleaved 
from the end (exo) or within a chain (endo), which constitutes another layer for DUBs 
specificity.52 Both mechanisms have been described with profoundly different 
consequences. For endo-DUBs, they must accommodate ubiquitin molecules on either 
side of the cleavage site with the ability to remove entire chains from target proteins, 
whereas for exo-DUBs, they only need to bind a single ubiquitin-the distal ubiquitin, 
cleaving only one ubiquitin moiety each time. Therefore, an endo-DUB would reverse 
polyubiquitination more efficiently in contrast with an exo-DUB.15 Further, DUBs may 
gain specificity by targeting a select set of substrates directly, while disassembling 
ubiquitin chains independently of the linkage type. These DUBs can specifically 
recognize ubiquitinated target proteins and carry out a single-step to remove 
monoubiquitin or polyubiquitin chains. Most USPs belong to this large group of DUBs, 
which can be considered nonspecific with regard to the ubiquitin linkage but specific 
with respect to their substrates, and can efficiently hydrolyze the isopeptide bond 
between the substrate and the first ubiquitin.55,56  
Consistent with its vast number and multiple layers of specificity, DUBs have 
been demonstrated to play diverse functions in distinct cellular pathways which can be 
classified into three major categories: ubiquitin precursor processing, ubiquitin 
deconjugation and editing of ubiquitin conjugates.51,52 Firstly, ubiquitin is synthesized as 
inactive precursors consisting of either multiple ubiquitin copies or ubiquitin fusions to 




expose the glycine carboxylate group that is the site of substrate conjugation. Thus, 
DUBs contribute to the generation of free ubiquitins through their ability to process 
ubiquitin precursors. Secondly, DUBs can remove the ubiquitin chains and play a critical 
regulatory role by counteracting ubiquitination of selective target proteins, leading to the 
reversion of ubiquitin signaling or to protein stabilization by rescuing them from 
degradative pathways, with associated activities of recycling ubiquitin molecules, 
thereby maintaining the cellular pool of free ubiquitins and contributing to ubiquitin 
homeostasis. Finally, some DUBs can trim ubiquitin chains conjugated to target proteins 
and alter the fates of target proteins in a more subtle way by editing the length and 
topology of its ubiquitin tag to change the signal (nondegradable vs degradable) 
harbored by them. For example, A20 can change receptor-interacting serine-threonine 
kinase 1 (RIPK1) ubiquitination status from Lys63- to Lys48-linked polyubiquitin 
chains, causing its degradation by the proteasome.36,53,67,68,70 
Owing to their specific catalytic activities and pivotal roles in ubiquitin 
homeostasis and control of protein stability, DUB activities must be tightly controlled 
within the cell through a number of different mechanisms, including post-translational 
modifications (PTMs), allosteric interactions and subcellular localization. First of all, 
many DUBs are subjected to PTMs, including phosphorylation and ubiquitination.71 
Specially, multiple DUBs can be tightly controlled by phosphorylation that can switch 
their activity on or off. For example, phosphorylation inhibits CYLD and USP8, while it 
activates A20, USP7, USP15, USP16, USP19, USP28, USP34 and USP37. 




exemplified in the case of ATXN3 catalytic activity activation and UCH-L1 activity 
inhibition by steric hindrance.50 Besides, certain DUBs, like UCH-L1, UCH-L3, OTU1, 
USP1, USP5, USP7, USP12, USP14 and USP46, contain ubiquitin-binding domains or 
ubiquitin-like motifs within their catalytic regions and are thought to undergo allosteric 
conformational changes upon interaction with ubiquitin or other proteins to obtain their 
active conformations, as another way to prevent uncontrolled proteolytic activity.56 Last 
but not least, several DUBs can also be modulated by changes in their subcellular 
localization and have been shown to undergo epidermal growth factor (EGF)-dependent 
translocation to endosomes which would facilitate their access to specific substrates for 
processing. The localization of USP30 to mitochondria seems to affect the 
morphological properties of this organelle, whereas USP36 special nucleolar localization 
can regulate its structure and function.15 
In the past decade, accumulating evidence indicates that DUBs regulate various 
pathways and proteins whose dysregulation is associated with numerous diseases 
spanning oncology, neurodegeneration, hematology and infectious diseases (Figure 
3).68,72-75 Representative examples are found within each DUB class, including USP1 
(Fanconi anaemia), USP2 (prostate cancer), USP7 (prostate cancer, viral infection), 
USP16 (Down’s syndrome), UCH-L1 (Parkinson’s disease), A20 (lymphoma), AMSH 
(Microcephaly-capillary malformation syndrome), and ATXN3 (ataxia). It is thus 
conceivable that targeting DUBs may be useful for the treatment of various diseases, 
especially for cancer therapy.70,76,77 Considerable interest in DUBs as potential drug 




academic and pharmaceutical companies alike over the past years. Overall, the 
development of small molecule inhibitors for DUBs is still in its infancy, although a 
number of putative small inhibitor molecules for the UCH and USP family members 
have been identified, none of them can be used therapeutically due to problems with 
specificity. The future development of DUB-based therapy will largely depend on 
further investigations of DUBs crystal structures, improvement of better HTS-





Figure 3. Six families of deubiquitinases (DUBs). DUBs can regulate numerous 
processes including cell homeostasis, protein stability, signal transduction and endocytic 





Scope of the Thesis 
This dissertation was focused on the design and development of novel chemical 
biology tools for deubiquitinating enzymes investigations, starting from the exploitation 
of E1-catalyzed ubiquitin C-terminal amidation reaction (Chapter II), which could be 
further applied in many aspects of DUB study, including efficient syntheses of 
physiological-based substrates for DUBs enzyme activity study (Chapter III), 
construction of topologically-characterized ubiquitin polymers (poly-Ub) mimics for 
DUBs specificity study (Chapter IV) and establishment of a readily-adoptable novel 
HTS assay for DUB inhibitors discovery (Chapter V). 
Firstly, in Chapter II, a straightforward single-step approach was illustrated to 
append numerous orthogonal functional groups (thiol, azide, alkyne, alkene, etc.) to the 
Ub C-terminus with high efficiency as well as high yield (> 90%) via E1-catalyzed 
ubiquitin C-terminal amidation reaction. This approach was based on the natural 
ubiquitination process and took full advantage of the high reactivity and universality of 
ubiquitin-activating enzyme (E1).The simple nature of the reaction, almost quantitative 
conversion rates and easy expressions of both Ub and E1 in E. coli allowed its wide 
application for functional Ub-amine conjugates production. 
Then, for those Ub-amine conjugates with various functional groups at the Ub C-
terminus, we further modified them (thiol, azide and alkyne) via click reactions to 
construct respective fluorescent ubiquitin conjugates for DUBs activity study, as 
described in Chapter III. The Ub-amine conjugates contained unique functionalities at 




conjugates, which could serve as the substrates for DUBs enzymatic kinetic study based 
on time-dependent fluorescence polarization change. By virtue of highly efficient click 
reactions, Ub-fluorophore conjugates could be synthesized quantitatively in one step, 
with relatively flexible linkages between Ub C-terminus and fluorophore groups, 
mimicking the natural isopeptide bond in ubiquitin chains and rendering them as suitable 
physiological-based substrates for DUBs activity study. 
Besides fluorescent ubiquitin conjugates, in Chapter IV, a universal method for 
preparing ubiquitin polymers (poly-Ub) mimics with distinct linkage types was 
illustrated. This method combined the high-efficient E1-catalyzed Ub C-terminal 
amidation reaction to append alkene groups to Ub C-terminus, together with thiol-ene 
coupling reaction to construct a flexible linkage between alkene and cysteine mutants in 
another ubiquitin molecule for the syntheses of poly-Ub mimics. Through introducing 
cysteine mutants to different lysine positions in the ubiquitin molecule, distinct linkage 
types between Ub molecules could be readily achieved, thus, this universal and 
straightforward method provided a novel route to construct polyubiquitin chains with 
desirable linkage types, which might greatly facilitate the research field of 
deubiquitinases cleavage specificity, whose development had been hampered by the 
limited availability of versatile poly-Ub chains for a long time. 
In addition of preparing diverse substrates for deubiquitinases activity study, we 
also developed a novel luminescent assay for high-throughput screening of DUBs 
inhibitors, which would be discussed in Chapter V. This assay was based on the 




which would release D-cysteine molecule for further reaction with 2-cyano-6-
hydroxybenzothiazole to afford luciferin for further luminescence production through 
luciferase enzyme catalyzed reaction at the presence of ATP and Mg2+. Compared to 
currently widely-applied fluorogenic assay with Ub-AMC (ubiquitin-7-amido-4-
methylcoumarin) as the starting substrate, our luminescent assay displayed lower signal 
noise and less intervention with library compounds; also, a more flexible linkage 
between Ub C-terminus and D-cysteine rendered Ub-D-Cys to be a better substrate than 
Ub-AMC for deubiquitinases recognition, which might be applied for inhibitors 







CHAPTER II  
DEVELOPMENT OF E1-CATALYZED UBIQUITIN C-TERMINAL AMIDATION 
REACTION FOR UBIQUITIN DERIVATIVES SYNTHESES* 
 
Introduction 
Ubiquitin (Ub) is a small but evolutionarily conserved polypeptide with 76 amino 
acids.82 In eukaryotes, it is covalently conjugated to cellular proteins through protein 
ubiquitination process in which an amide bond (isopeptide or peptide) is formed between 
the Ub C-terminal carboxylate group and a lysine side-chain amino group or N-terminal 
amino group of a protein substrate. This process is orchestrated by sequential actions of 
three types of enzymes, namely, Ub-activating enzyme (E1), Ub-conjugating enzyme 
(E2), and Ub ligase enzyme (E3).24,37,42 In mammalian cells, the ubiquitination cascade 
is pyramidal in design. One E1 enzyme can transfer Ub to dozens of E2 enzymes, which 
function together with hundreds of different E3 enzymes to guarantee ubiquitination 
specificities. Protein ubiquitination is one of the most significant post-translational 
modifications in eukaryotes and is the key regulator for numerous substrate proteins and 
various cellular processes.43 
In the protein ubiquitination process, initially, E1 enzyme catalyzes two 
sequential reactions to activate Ub. The first reaction involves Ub and ATP to form Ub-
                                                 
* Reprinted (adapted) with permission from “E1-Catalyzed Ubiquitin C-Terminal Amidation for 
the Facile Synthesis of Deubiquitinase Substrates” by Wang, X. A.; Kurra, Y.; Huang, Y.; Lee, 
Y. J.; Liu, W. R. Chembiochem 2014, 15, 37-41. Copyright © 2014 WILEY-VCH Verlag GmbH 




AMP that then reacts with the E1 active-site cysteine to form an E1-Ub fusion with a 
thioester linkage.16,17 In the presence of an E2 enzyme, the E2 active-site cysteine 
intercepts Ub from E1-Ub and then transfers Ub to a lysine side-chain amino group or 
N-terminal amino group of a target protein while an E3 enzyme serves as a catalyst in 
this transfer.18,19 Although considered labile, the thioester bond in an E1-Ub fusion 
upholds relatively stable E1-Ub linkage in the absence of E2, which could be readily 
detected by non-reductive SDS-PAGE analysis as previously reported by Azevedo’s 
group for determining E1 enzyme’s activity.83 Also, the same E1-Ub thioester bond was 
effectively employed to undergo native chemical ligation with peptides that contained a 
N-terminal cysteine or a mercapto-lysine entity pioneered by Ashraf Brik84 and Chuan-
Fa Liu85,86 for functional ubiquitin derivatives syntheses. More recently, exchanging E1 
in the E1-Ub thioester bond with 2-mercaptoethanesulfonate to form a Ub thioester 
linkage was reported by Fushman’s group for polyubiquitin chains preparation.87 Based 
on these previous studies, we reasoned that this E1-Ub thioester, in the absence of E2, 
could potentially undergo the aminolysis reaction with a primary amine to form a C-
terminal functionalized Ub derivative and recover E1.21 When this happened, E1 would 
essentially serve as an enzyme to catalyze Ub C-terminal conjugation in the presence of 
ATP and a primary amine.  
With this hypothesis, we initiated our test of this E1-catalyzed ubiquitin C-
terminal amidation reaction with a number of different primary amines, including 
cysteamine, hydrazine, hydroxylamine, azidoethylamine, propargylamine, and 




reaction conditions, such as pH, temperature, concentrations and reaction time. 
Compared to two major methods for ubiquitin derivatives preparation-total chemical 
synthesis and native chemical ligation, this novel and facile single-step approach is 
exceptionally simple and unique and can be readily adopted by a regular biochemistry 
and molecular biology group that is either not equipped or not capable to handle organic 




Figure 4. Scheme of E1-catalyzed amidation reaction to functionalize Ub C-terminus 





Experimental Details  
General Experimental Information 
All reactions involving moisture sensitive reagents were conducted in oven-dried 
glassware under an argon atmosphere. Anhydrous solvents were obtained through 
standard laboratory protocols. Analytical thin-layer chromatography (TLC) was 
performed on Whatman SiO2 60 F-254 plates. Visualization was accomplished by UV 
irradiation at 254 nm or by staining with ninhydrin (0.3% w/v in glacial acetic acid/n-
butyl alcohol 3:97). Flash column chromatography was performed with flash silica gel 
(particle size 32-63 µm) from Dynamic Adsorbents Inc (Atlanta, GA). 
Specific rotations of chiral compounds were obtained at the designated 
concentration and temperature on a Rudolph Research Analytical Autopol II polarimeter 
using a 0.5 dm cell. Proton and carbon NMR spectra were obtained on Varian 300 and 
500 MHz NMR spectrometers. Chemical shifts are reported as δ values in parts per 
million (ppm) as referenced to the residual solvents: chloroform (7.27 ppm for 1H and 
77.23 ppm for 13C) or water (4.80 ppm for 1H). A minimal amount of 1, 4-dioxane was 
added as the reference standard (67.19 ppm for 13C) for carbon NMR spectra in 
deuterium oxide, and a minimal amount of sodium hydroxide pellet was added to the 
NMR sample to aid in the solvation of amino acids which have low solubility in 
deuterium oxide under neutral or acidic conditions. 1H NMR spectra are tabulated as 
follows: chemical shift, multiplicity (s = singlet, bs = broad singlet, d = doublet, t = 




spectra were obtained at the Laboratory for Biological Mass Spectrometry at the 
Department of Chemistry, Texas A&M University.109 
2-Azido-ethylamine hydrochloride was synthesized following the procedure 
below. All other reagents were obtained from commercial suppliers and used as 
received.  
Chemical Synthesis 
Synthesis of 2-azido-ethylamine hydrochloride 
 To a 250 mL of round-bottom-flask 2-bromoethyl amine (1, 5 g, 24.5 mmol) 
was added, followed by tetrahydrofuran (THF) (50 mL) and NaOH aqueous (1.0 M, 
26.95 mL, 26.95 mmol). The reaction mixture was cooled to 0°C. Di-tert-butyl 
dicarbonate (5.87 g, 26.96 mmol) was dissolved in THF (50 mL) and added to the above 
mixture dropwise over 40 min. Then the resulting mixture was stirred at room 
temperature for 20 hours. THF was removed under reduced pressure. The residue was 
diluted with water (50 mL), and extracted with EtOAc (50 mL). The aqueous layer was 
collected and acidified to pH = 3 with HCl (1.0 M in water), then extracted with EtOAc 
(50 mL×3). The combined organic layers were dried over anhydrous Na2SO4, 
concentrated under reduced pressure and purified by flash chromatography to afford 
compound 2 (4.86 g, 90% yield). Compound 2 (4.5g, 20.07 mmol) was dissolved in N,N-
dimethylformamide (DMF) (100 mL). NaN3 (6.5 g, 100.39 mmol) was added, and the 
mixture was stirred at 110°C for 12 hours. The solvent was removed under reduced 
pressure, and the residue was dissolved in water (100 mL). The resulting aqueous 




and dried over anhydrous MgSO4(s). After filtration, the organic layer was concentrated 
under reduced pressure and the residue was dissolved in methylene chloride (10-20 mL) 
and purified by flash chromatography with 70% pure compound 3 (2.61 g). A 
suspension of compound 3 (2.61 g, 10.30 mmol) in dioxane and 4N HCl (7.0 mL, 2 eq.) 
was added as dropwise at room temperature and the reaction mixture was stirred at room 
temperature for 16 hours. The solid was collected by filtration to obtain 2-azido-
ethylamine hydrochloride (4, 1.02 g, 60%). 1H NMR (300 MHz, CD3OD) δ = 3.76-3.68 
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Construction of Plasmids 
Plasmid pETDuet-w.t.Ub 
The plasmid pETDuet-w.t.Ub bearing the gene encoding w.t.Ub was constructed 
from the pETDuet-1 vector (Stratagene Inc.). In this plasmid, w.t.Ub is under the control 
of IPTG-inducible T7 promoter. 
Protein Expression and Purification 
Wild-type ubiquitin expression and purification 
To express wild-type ubiquitin (w.t.Ub), Escherichia coli (E. coli) BL21 cells 
were transformed with pETDuet-w.t.Ub plasmid. A starter culture was grown in 




overnight. The culture was then inoculated into 2×YT media (1 L) with the same 
concentration of ampicillin the next morning. Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) (0.5 mM) was added into the cell culture after the OD600 reached 0.9~1.1. The 
cell culture was incubated at 37°C for 8 hours, and the cells were harvested by 
centrifugation at 4,000 r.p.m. for 30 min at 4°C and resuspended in 50 mL of lysis buffer 
(140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, 10 mM imidazole, 
pH 7.4). The resuspended cells were sonicated in an ice/water bath for four times (3 min 
each, 10 min interval to cool down the suspension to below 10°C before the next run) 
and the lysate was clarified by centrifugation at 10,000 r.p.m. for 40 min at 4°C. The 
supernatant was then incubated in a 75°C water bath for 1 hour and then centrifuged at 
10,000 r.p.m for 40 min at 4°C for further purification. The concentration of w.t.Ub 
protein was determined by BCA (bicinchoninic acid) protein assay kit from Thermo 
Fisher Scientific Inc. (Rockford, IL). According to the concentration, wild-type ubiquitin 
expression yield was around 160 mg/L from the 2×YT media. 
Histidine tagged-mouse ubiquitin-activating enzyme (Histag-mE1) expression and 
purification 
pET28b-mE1 plasmid was purchased from Addgene (Plasmid #32534). To 
express ubiquitin-activating enzyme (E1), E. coli BL21 (DE3) codon plus cells were 
transformed with pET28b-mE1. The expression was adapted from the procedure stated 
in Andreia’s paper published in 2012.83 A starter culture was grown in 2×YT media (5 
mL) with 34 µg/mL chloramphenicol and 25 µg/mL kanamycin at 37°C overnight. The 




antibiotics the next morning. The culture was cooled down to 16°C after the OD600 
reached 0.9~1.1 and then added isopropyl β-D-1-thiogalactopyranoside (IPTG) (0.5 mM). 
The culture continued to grow for another 20 hours at 16°C. Then the cells were pelleted, 
resuspended in 50 mL of lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 0.1% (w/v) 
Triton X-100, 1 mM EDTA-NaOH, 1 mM dithiothreitol (DTT), 0.1 mg/mL 
phenylmethylsulfonyl fluoride (PMSF), and 1:500 (v/v) Sigma mammalian protease 
inhibitor mixture, pH 8.0), and then sonicated in an ice/water bath for four times (3 min 
each, 10 min interval to cool down the suspension to below 10°C before the next run). 
The lysate was clarified by centrifugation at 10,000 r.p.m. for 40 min at 4°C. The 
clarified supernatant was incubated with 2 mL of Ni SepharoseTM 6 Fast Flow beads 
from GE Healthcare (Little Chalfont, United Kingdom) for 20 min for the purpose of 
effectively binding and then poured into a 10-mL empty purification column to allow the 
Ni sepharose beads to settle completely by gravity. The Ni sepharose beads were then 
washed with 50 mL buffer A (50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 
7.8) to get rid of any unspecific binding proteins and subsequently eluted out with 12 mL 
of buffer B (50 mM NaH2PO4, 300 mM NaCl, 300 mM imidazole, pH 7.8). The eluted 
solution was concentrated by Amicon Ultra-15 centrifugal filter units - 30,000 NMWL 
from Millipore (Billerica, MA) to 1 mL by centrifugation at 4,000 r.p.m. at 4°C. The 
buffer was then changed to the stock buffer (10 mM Tris-HCl, 1 mM EDTA-NaOH, 1 
mM DTT, pH 8.0) by dialysis. Recombinant histidine-tagged mouse E1 (mE1) protein at 
10 mg/mL was divided into small aliquots, frozen in liquid nitrogen, and stored at -80°C. 




Fisher Scientific Inc. (Rockford, IL). According to the concentration, mE1 expression 
yield was around 10 mg/L from the 2×YT media. 
E1 Activity Assay 
For E1 activity assay, aliquots of nickel affinity purified mouse E1 stored 
at -80°C were rapidly thawed and placed on ice. Thiol ester assays were performed in 20 
µL (final volume) of the buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid (HEPES), 250 mM sucrose, 50 mM KCl, 3 mM MgCl2, pH 7.4) in the presence of 5 
mM ATP. Reactions contained 12 μM of w.t.Ub and 400 nM recombinant mouse E1. 
Incubation was done at 37°C for 30 min. Reactions were then treated with 10 mM N-
ethylmaleimide (NEM) for 5 min on ice and then subjected to SDS-PAGE analysis 
under non-reducing conditions. 
E1-Catalyzed Amidation Reaction for the Syntheses of Functional Ub Derivatives 
Aliquots of purified mouse E1 stored at -80°C were rapidly thawed and placed on 
ice. For cysteamine, the reaction solution containing 250 µM w.t.Ub, 2 µM E1, 2 mM 
ATP, 5 mM cysteamine (pre-reduced by 5 mM tris(2-carboxyethyl)phosphine (TCEP)) 
was incubated in a 1 mL (final volume) buffer (50 mM HEPES, 250 mM sucrose, 50 
mM KCl, 3 mM MgCl2, pH 7.4) at 4°C overnight. For hydrazine and hydroxylamine, 
their reactions were performed in 1 mL (final volume) buffer (50 mM HEPES, 250 mM 
sucrose, 50 mM KCl, 3 mM MgCl2, pH 7.4) with 2 µM mouse E1, 250 µM w.t.Ub, 2 
mM ATP, and 50 mM hydrazine or hydroxylamine, respectively. The mixtures were 




propargylamine and allylamine), their reactions were performed in the 1 mL (final 
volume) buffer (10 mM N-cyclohexyl-3-aminopropanesulfonic acid (CAPS), 250 mM 
sucrose, 50 mM KCl, 3 mM MgCl2, pH 9.4), and consisted of 250 µM Ub, 5 µM E1, 5 
mM ATP, and 750 mM respective amines. The mixtures were incubated at 37°C 
overnight. The conversion of each reaction was determined by ESI-MS analysis. 
Protein ESI-MS Analysis for Determining E1-Catalyzed Amidation Reaction Yield 
An Agilent (Santa Clara, CA) 1200 capillary HPLC system was interfaced to an 
API QSTAR Pulsar Hybrid QTOF mass spectrometer (Applied Biosystems/MDS Sciex, 
Framingham, MA) equipped with an electrospray ionization (ESI) source. The mass 
spectrometry (MS) data were acquired in positive ion mode (500-2,000 Da) using spray 
voltage of +2,700 V. BioAnalyst software (Applied Biosystems) was used for spectral 
deconvolution. A mass range of m/z 500-2,000 was used for deconvolution and the 





Results and Discussion 
First of all, wild-type ubiquitin and mouse ubiquitin-activating enzyme (mE1) 
were expressed in E.coli cells and further purified by respective purification methods 
described in the experimental details. The purity of the proteins was judged by SDS-
PAGE analysis shown in Figure 6. With the purified wild-type ubiquitin and mouse 
ubiquitin-activating enzyme (mE1), we further performed a thiol ester assay to test 
whether the recombinant mouse E1 produced in E. coli cells was active. In this assay, E1 
activity was assessed by the capacity of the enzyme to form a thiol ester conjugate with 
ubiquitin in an ATP-dependent process.  As shown in Figure 7, when the nickel affinity 
purified mouse E1 was incubated with wild-type ubiquitin in the presence of ATP, a 
species migrating slower than the E1 protein was formed (lanes 3, Ub + E1) under non-
reducing SDS-PAGE conditions. It was noteworthy that essentially all E1 enzyme was 
able to form a thiol ester bond with wild-type ubiquitin, indicating that the recombinant 
E1 enzyme was fully active. 
After confirmation of E1 enzyme activity, we further tested the hypothesized E1-
catalyzed Ub C-terminal amidation reaction starting with hydrazine as a primary amine. 
After 2 µM mouse E1, 250 µM wild-type ubiquitin, 2 mM ATP, and 50 mM hydrazine 
were incubated at pH 7.4 and 37°C for overnight, w.t.Ub was almost quantitatively 
converted to a Ub-hydrazine conjugate. It displayed a peak at 8,578 Da detected by 
electrospray ionization mass spectrometry (ESI-MS) that agreed well with its theoretic 
molecular weight (8,578 Da) (Figure 9), and little w.t.Ub was left as unreacted with the 




embarked on testing E1-catalyzed Ub C-terminal amidation reaction with other amines 
including hydroxylamine, cysteamine, azidoethylamine, propargylamine, and allylamine. 
By optimizing reaction conditions (pH, temperature, amine concentrations, etc.), we 
successfully converted w.t.Ub to all five corresponding Ub-amine conjugates with yields 
higher than 90%. Hydroxylamine was similar to hydrazine which could be successfully 
appended to Ub C-terminus using the same reaction condition as hydrazine. Cysteamine 
reacted efficiently at 5 mM due to the existence of the β-thiol group. At physiological 
pH, the thiol group could perform the transthioesterification reaction with Ub-E1 
thioester bond to form a Ub-cysteamine conjugate with a thioester linkage that could 
subsequently undergo S to N acyl transfer to regenerate the free thiol group as well as 
forming a stable amide linkage between Ub and cysteamine.90,91 This process resembled 
the cysteine-mediated native chemical ligation (NCL) reaction,92 eliciting a higher 
reactivity of cysteamine. On the contrary, for the other three primary amines (2-azido-
ethylamine, propargylamine, and allylamine), the concentration of amines needed to be 
more than 500 mM for efficient conversion and the reactions were conducted with a pH 
close to 9 to maintain high levels of alkaline forms of primary amines for efficient 
nucleophilic attacks to the thioester bond of Ub-E1 fusion protein to generate the inert 
amide bond directly. With elevated concentrations of both nucleophiles and E1, 
efficiencies for formation of Ub-amine conjugates from 2-azido-ethylamine, 
propargylamine, and allylamine were achieved to levels similar as cysteamine.  
The theoretical molecular weights of wild-type Ub, Ub-hydrazine, Ub-




azidoethylamine were 8,564, 8,578, 8,579, 8,623, 8,603, 8,601 and 8,632 Da, 
respectively (Table 1). The ESI-MS analysis confirmed the successful syntheses of all 




Figure 6. Coomassie-stained SDS-PAGE analyses of wild-type ubiquitin (A) and mouse 
ubiquitin-activating enzyme (mE1) (B). (A) w.t.Ub was expressed in E. coli BL21 cells. 
(B) mE1 was expressed in E. coli BL21(DE3) codon plus cells and purified with Ni 








Figure 7. Coomassie-stained SDS-PAGE analysis of E1 activity assay under non-
reducing (no DTT) conditions. w.t.Ub, mE1, and reaction mixture of w.t.Ub and mE1 









Table 1. List of theoretical molecular weights (MW) and detected molecular weights by 
ESI-MS for w.t.Ub and Ub-amine conjugates. 
w.t.Ub/Ub-amine conjugates Theoretical MW (Da) Detected MW (Da) 
w.t.Ub 8,564 8,565 
Ub-hydrazine 8,578 8,579 
Ub-hydroxyamine 8,579 8,580 
Ub-cysteamine 8,623 8,623 
Ub-allylamine 8,603 8,604 
Ub-propargylamine 8,601 8,601 






Figure 8. Deconvoluted ESI-MS spectra of wild-type ubiquitin (w.t.Ub). The theoretical 
molecular weight of wild-type Ub was 8,564 Da. The detected molecular weight of wild-





Figure 9. Deconvoluted ESI-MS spectra of Ub-hydrazine. The theoretical molecular 
weight of Ub-hydrazine was 8,578 Da. The detected molecular weight of Ub-hydrazine 





Figure 10. Deconvoluted ESI-MS spectra of Ub-hydroxylamine. The theoretical 
molecular weight of Ub-hydroxylamine was 8,579 Da. The detected molecular weight of 





Figure 11. Deconvoluted ESI-MS spectra of Ub-cysteamine. The theoretical molecular 
weight of Ub-cysteamine was 8,623 Da. The detected molecular weight of Ub-





Figure 12. Deconvoluted ESI-MS spectra of Ub-allylamine. The theoretical molecular 
weight of Ub-allylamine was 8,603 Da. The detected molecular weight of Ub-allylamine 





Figure 13. Deconvoluted ESI-MS spectra of Ub-propargylamine. The theoretical 
molecular weight of Ub-propargylamine was 8,601 Da. The detected molecular weight 





Figure 14. Deconvoluted ESI-MS spectra of Ub-azidoethylamine. The theoretical 
molecular weight of Ub-azidoethylamine was 8,632 Da. The detected molecular weight 





Conclusions and Outlook 
In summary, by virtue of natural ubiquitination process, we took advantage of the 
high reactivity and universality of ubiquitin-activating enzyme (E1) to install various 
functional groups onto the Ub C-terminus by an amidation reaction, which provided a 
novel straightforward approach to generate functional ubiquitin conjugates that could be 
further modified into various types of DUB substrates for DUBs functional studies and 
high-throughput screening (HTS) of DUBs inhibitors. The simple nature of the E1-
catalyzed ubiquitin C-terminal amidation process, high efficiency of the reaction itself, 
and the easy expression of both wild-type Ub93 and E1enzyme83 in E. coli cells allowed 
efficient large-scale production of multiple Ub-amine conjugates. We could routinely 
obtain Ub-amine conjugates to half-gram scales. Another important advantage of this 
E1-catalyzed amidation reaction was the robust and straightforward chemistry used to 
append Ub C-terminus with multiple unique functionalities, allowing a regular 
biochemistry and molecular biology research group to readily adopt this simple method. 
We believed that the application of this method would greatly accelerate studies of 
DUBs that play pivotal roles in numerous cellular pathways but whose investigations 
were greatly hampered by the difficulty in the accessibility of suitable DUB substrates.  
Previously, the intein fusion method to recombinantly express Ub(1-75)-intein 
and SUMO(GG)-intein thioesters followed by exchanging them with primary amines 
was widely used to append functional groups to Ub and SUMO (Small ubiquitin-like 
modifier) in which one or two C-terminal glycine(s) were removed.94,95 Although the 




relative low yield of intein fusion expression, the labile nature of the Ub-thioester, and 
the stoichiometric nature of the exchange reaction with amines would lead to low yields. 
In comparison to the intein fusion approach, this E1-catalyzed amidation reaction 
method was much more robust and practical.  
Recently, other ubiquitin-like (Ubl) proteins which comprise a diverse group of 
evolutionarily conserved small proteins that are covalently conjugated to target proteins, 
thereby regulating their function, have been discovered. Although they vary in their 
degree of primary sequence similarity to ubiquitin, they all seem to be conjugated 
through a comparable enzymatic cascade: Ubl proteins are initially activated through 
adenylation of their C-terminal glycine-glycine motif and subsequently form a thioester 
bond with their specific activating E1 enzymes; then they are transferred to their 
respective conjugating E2 enzymes by transthioesterification reaction and are finally 
conjugated to ε-amino groups of lysine residues in specific target proteins with the help 
of ligating E3 enzymes.96 Hence, we inferred that this E1-catalyzed amidation reaction 
could also be utilized to functionalize the C-termini of other Ubl proteins, which would 
lead to the syntheses of various functional Ubl-amine conjugates for the activity studies 
of their respective deconjugating enzymes. Since the small ubiquitin-like modifier 
(SUMO) is one of the most studied among nearly 20 types of discovered Ubl proteins so 
far besides ubiquitin, and has been found to be involved in diverse cellular processes 
(including transcription, replication, chromosome segregation and DNA repair);44,45 also, 
the expression and purification procedure for SUMO-specific activating E1 enzyme 




E1-catalyzed amidation reaction method could be potentially applied to functionalize 
SUMO C-terminus as well to synthesize functional SUMO-amine conjugates for the 





CHAPTER III  
SYNTHESES OF FLUORESCENT UBIQUITIN CONJUGATES AS 
DEUBIQUITINASE SUBSTRATES FOR KINETIC STUDY* 
 
Introduction 
Protein ubiquitination is defined as the process in which a single ubiquitin (Ub) 
entity is tagged to one or multiple lysine sites through a concerted three-step enzymatic 
cascade recruiting three types of enzymes: Ub-activating enzyme (E1), Ub conjugating 
enzyme (E2), and Ub ligase enzyme (E3).9,10,23,29,98 The reversed process can be 
achieved by deubiquitinases (or deubiquitinating enzymes, DUBs).15 To date, it has been 
found that the human genome encodes around 100 DUBs, which can be divided into six 
structurally unrelated families (USP, UCH, OTU, MJD, MCPIP, and JAMM) for 
specifically deconjugating Ub from target proteins. The activities of these enzymes are 
crucial for cell homeostasis, protein stability, and a wide range of signaling pathways, 
while their misregulations have been implicated in the pathogenesis of many human 
diseases, including chronic inflammatory diseases and various types of cancer; thus, 
DUBs, as an emerging potential drug targets, have attracted increasing interest from not 
only researchers but also the pharmaceutical industry.48,55,99,100  
                                                 
* Reprinted (adapted) with permission from “E1-Catalyzed Ubiquitin C-Terminal Amidation for the Facile 
Synthesis of Deubiquitinase Substrates” by Wang, X. A.; Kurra, Y.; Huang, Y.; Lee, Y. J.; Liu, W. R. 




The mounting interest in DUBs has promoted DUB studies as well as DUB 
inhibitor discoveries.81 One prerequisite of DUB research is the preparation of large 
amounts of DUB assay reagents such as fluorescent Ub-based substrates and multiple 
polyubiquitin chains for in vitro analysis.15 Fluorogenic ubiquitin molecules that can 
serve as DUB substrates have been made available from several commercial 
providers.101,102 The most popular substrate, Ub-AMC is the fusion protein of the 
ubiquitin carboxyl terminus to 7-amino-4-methylcoumarin (AMC) with an amide 
linkage. The major drawback of Ub-AMC is that some DUBs fail to recognize and 
cleave the relatively bulky and hydrophobic 7-amino-4-methylcoumarin group.103 
Another downside of most commercially available fluorogenic ubiquitin substrates is the 
fact that they don’t have the isopeptide bond found in native ubiquitinated proteins. 
Fluorescent ubiquitin substrates with a native isopeptide linkage were recently 
synthesized through native chemical ligation in coordination with organic synthesis.81,104 
However, the relatively complicated synthetic routes prevented widespread adoption of 
this approach. The limited availability of suitable DUB substrates, to a large extent, 
hampered the development of DUB research for a long time. To facilitate functional 
investigations of DUBs and accelerate drug discovery for DUB-targeted disease 
intervention, we developed a simple but readily adoptable approach to functionalize the 
ubiquitin C-terminus for further syntheses of various fluorescent ubiquitin conjugates 
that can serve as DUB substrates. 
In preliminary studies, we successfully employed ubiquitin-activating enzyme 




unique functionalities at the ubiquitin C-terminus. Theoretically, three of them (thiol, 
azide, and alkyne) could further undergo covalent modifications with respective 
fluorophores to be selectively labeled and yield fluorescent ubiquitin conjugates. For 
Ub-cysteamine, since wild-type ubiquitin naturally doesn’t contain a cysteine residue 
itself, its thiol group could be exclusively targeted by molecules with chemical entities 
such as haloacetamide and maleimide.105,106 While for Ub-propargylamine and Ub- 
azidoethylamine, they contained a terminal alkyne or azide group, which could undergo 
the Cu (I)-catalyzed azide-alkyne Huisgen cycloaddition reaction.107,108 Thus, all these 
three ubiquitin-amine conjugates could be selectively labeled with respective fluorescent 
dyes, while wild-type ubiquitin itself would not react with those dyes under the same 
reaction conditions.109-111  
For these three fluorescent ubiquitin conjugates, they could serve as substrates 
for the study of DUBs activity by following the time-dependent fluorescence 
polarization change after treatment with DUBs. The principle of fluorescence 
polarization derives from the fact that the degree of polarization of a fluorophore is 
inversely related to its molecular rotation. For a fluorophore that is covalently attached 
to a small molecule, when it is excited by polarized light, it would emit predominantly 
depolarized light, whereas for a fluorophore that is bound to a high molecular weight 
molecule such as ubiquitin, the emitted light would be much less depolarized.112-115 
During DUB-catalyzed deconjugation reaction, fluorophores conjugated to ubiquitin C-
terminus would be released as small molecules, leading to a fluorescence polarization 




DUB cleavage activities on these substrates could be monitored effectively. Therefore, 
we applied the E1-catalyzed Ub C-terminus amidation reaction to the facile syntheses of 
three novel fluorescent ubiquitin conjugates which could serve as deubiquitinases 





Figure 15. (A) Scheme of deconjugation reactions of fluorescent ubiquitin conjugates 
catalyzed by DUBs. (B) Fluorescence polarization comparison between fluorescent 








Synthesis of 2-azidoethanol (6)109 
To a solution of 2-chloroethanol (5, 25.2 g, 0.31 mol) in water (80 mL), sodium 
azide (26.3 g, 0.40 mol) and tetrabutylammonium bromide (2.0 g, 6.2 mmol) were 
added, and the mixture was stirred at room temperature for 2 hours before being 
heated at 120°C for 2 hours. Sodium chloride was added to the cooled yellow solution 
until saturation, and the mixture was extracted with ethyl acetate (60 mL×3). The 
combined organic layers were dried (anhydrous MgSO4), filtered, and evaporated to 
give a crude yellow oil (31 g). Distillation under an oil pump-generated vacuum 
(~0.1 mmHg, bp 87-90°C) afforded 6 (14.9 g, 55%) as a colorless oil. 1H NMR 
(CDCl3, 500 MHz) δ 3.80-3.78 (m, 2 H), 3.46 (t, 2 H, J = 5.0 Hz), 1.88 (bs, 1 H); 13C 
NMR (CDCl3, 125 MHz) δ 61.7, 53.7. 
Synthesis of 2-azidoethyl chloroformate (7)109 
To a solution of 6 (82 mg, 0.94 mmol) in anhydrous dichloromethane (0.5 mL), 
trichloromethyl chloroformate (0.13 mmol, 1.1 mmol) was added, and the mixture was 
stirred at room temperature for 12 hours. The volatiles were evaporated to leave crude 7 
(0.14 g, quant.) as a yellow oil which was used without further purification. 1H NMR 
(CDCl3, 500 MHz) δ 4.43 (t, 2 H, J = 5.2 Hz), 3.63 (t, 2 H, J = 5.0 Hz). 
Synthesis of 5-((2’-azidoethyl)oxycarbonylamino) fluorescein (9)109 
To a solution of fluorescein amine isomer I (8, 0.20 g, 0.58 mmol) (Aldrich) in 




added dropwise over 5 min with the aid of a small amount of anhydrous 
dichloromethane (0.1 mL). The mixture was then stirred at room temperature for 48 
hours, and water (5 mL) was added. The mixture was diluted in ethyl acetate (50 mL), 
washed with water (10 mL), hydrochloric acid (0.1 N, 10 mL) and brine (10 mL), dried 
(Na2SO4), evaporated, chromatographed (EtOAc/hexanes, 1:1), and crystallized in ethyl 
acetate/hexanes to give 9 (0.11 g, 41%) as an orange solid. 1H NMR (DMSO-d6, 500 
MHz)  δ 10.32 (s, 1 H), 10.12 (s, 2 H), 8.12 (s, 1 H), 7.78 (dd, 1 H, J = 8.5, 1.5 Hz), 7.20 
(d, 1 H, J = 8.5 Hz), 6.66 (d, 2 H, J = 2.0 Hz), 6.59 (d, 2 H, J = 8.5 Hz), 6.54 (dd, 2 H, J 
= 8.7, 2.2 Hz), 4.31 (t, 2 H, J = 4.7 Hz), 3.65 (t, 2 H, J = 5.2 Hz) (Figure 16); 13C NMR 
(DMSO-d6, 75 MHz) δ 168.6, 159.5, 153.3, 151.9, 146.2, 140.7, 129.1, 127.1, 125.7, 
124.6, 112.6, 112.4, 109.7, 102.2, 83.3, 63.1, 49.7 (Figure 17); HRMS (ESI) calcd for 









Figure 16. 1H NMR spectrum for 5-((2’-azidoethyl)oxycarbonylamino) fluorescein 
(9).109* 
  
                                                 
* Reprinted with permission from “Catalyst‐Free and Site‐Specific One‐Pot Dual‐Labeling of a Protein 
Directed by Two Genetically Incorporated Noncanonical Amino Acids” by Wu, B.; Wang, Z. Y.; Huang, 







Figure 17. 13C NMR spectrum for 5-((2’-azidoethyl)oxycarbonylamino) fluorescein 
(9).109* 
  
                                                 
* Reprinted with permission from “Catalyst‐Free and Site‐Specific One‐Pot Dual‐Labeling of a Protein 
Directed by Two Genetically Incorporated Noncanonical Amino Acids” by Wu, B.; Wang, Z. Y.; Huang, 





Synthesis of 5-(propargyloxycarbonylamino) fluorescein (10)111 
To a solution of fluoresceinamine isomer I (8, 0.102 g, 0.29 mmol) (Aldrich) in 
anhydrous pyridine (1.0 mL) cooled in an ice bath, propargyl chloroformate (58 µL, 0.59 
mmol) was added dropwise, and the mixture was stirred at room temperature for 30 
hours. Ethyl acetate (50 mL) was then added, and the solution was washed with water 
(10 mL), saturated sodium bicarbonate (10 mL), hydrochloric acid (1 N, 10 mL) and 
brine (10 mL), dried (Na2SO4), evaporated, and flash chromatographed (EtOAc/hexanes, 
1:1) to give a yellow oil, which was dissolved in a minimal amount of ethyl acetate (~0.5 
mL) and precipitated with excessive hexanes (~10 mL) to afford 10 (66 mg, 52%) as a 
bright orange solid. Rf = 0.55 (EtOAc/hexanes, 2:1); 1H NMR (CD3OD, 500 MHz) δ 
8.17 (s, 1 H), 7.76 (dd, 1 H, J = 8.5, 2.0 Hz), 7.13 (d, 1 H, J = 9.0 Hz), 6.67 (d, 2 H, J = 
2.5 Hz), 6.65 (d, 2 H, J = 9.0 Hz), 6.54 (dd, 2 H, J = 8.5, 2.5 Hz), 4.82 (d, 2 H, J = 2.5 
Hz), 2.97 (t, 1 H, J = 2.5 Hz) (Figure 18); 13C NMR (CD3OD, 75 MHz) δ 171.6, 162.3, 
155.0, 154.6, 142.3, 130.5, 126.7, 126.2, 114.9, 114.1, 111.9, 103.6, 79.2, 76.4, 53.6 









Figure 18. 1H NMR spectrum for 5-(propargyloxycarbonylamino) fluorescein (10).111* 
                                                 
* Reprinted with permission from “A Facile System for Genetic Incorporation of Two Different 
Noncanonical Amino Acids into One Protein in Escherichia coli” by Wan, W.; Huang, Y.; Wang, Z. Y.; 
Russell, W. K.; Pai, P. J.; Russell, D. H.; Liu, W. R. Angew. Chem. Int. Ed. 2010, 49, 3211. Copyright © 





Figure 19. 13C NMR spectrum for 5-(propargyloxycarbonylamino) fluorescein (10).111*  
  
                                                 
* Reprinted with permission from “A Facile System for Genetic Incorporation of Two Different 
Noncanonical Amino Acids into One Protein in Escherichia coli” by Wan, W.; Huang, Y.; Wang, Z. Y.; 
Russell, W. K.; Pai, P. J.; Russell, D. H.; Liu, W. R. Angew. Chem. Int. Ed. 2010, 49, 3211. Copyright © 





Procedure for thiol group labeling 
25 µM Ub-cysteamine in 50 mM Tris-HCl buffer (pH 7.4) was pre-reduced by 
0.5 mM DTT at 37°C for 5 hours. After that, 2 mM 5-iodoacetamidofluorescein (5-IAF) 
(Pierce Biotechnology) (11, stock solutions in DMSO) was added and then incubated at 
4°C for 5 hours in the dark. The labeled protein was precipitated by adding nine volumes 
of HPLC-grade methanol at -20°C and collected by centrifuge at 4°C at 13, 000 r.p.m. 
for 15 minutes. The pellets were washed with ice-cold methanol for five times and then 
dissolved in PBS buffer (140 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM 
KH2PO4, pH 7.4). The labeled protein was subjected to SDS-PAGE analysis and 
electrospray ionization mass spectrometry (ESI-MS). 
Procedure for copper (I)-catalyzed azide-alkyne cycloaddition (CuAAC) labeling 
To 25 µM Ub-propargylamine or Ub-azidoethylamine in 50 mM Tris-HCl buffer 
(pH 7.4), CuSO4 (100 µM), NiCl2 (1 mM), tris[(1-benzyl-1H-1,2,3-triazol-4-
yl)methyl]amine (TBTA, stock solution in DMSO, 500 µM) and  their respective dyes (9 
or 10, stock solutions in DMSO, 1.25 mM) were added sequentially, followed by sodium 
ascorbate (5 mM). The reactions were performed at room temperature for 5 hours. Then 
ethylenediaminetetraacetic acid (EDTA, pH 8.0, 50 mM final concentration) was added 
to the reaction mixture to chelate the two metals to quench the reaction. The labeled 
proteins were precipitated by adding nine volumes of HPLC-grade methanol at -20°C 
and collected by centrifuge at 4°C at 13, 000 r.p.m. for 15 minutes. The pellets were 




NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 1.8 mM KH2PO4, pH 7.4). The labeled proteins 
were subjected to SDS-PAGE analysis and electrospray ionization mass spectrometry 
(ESI-MS). 
Fluorescence Polarization-based Assays for UCH-L3 Activity Study 
Fluorescence polarization-based assays were performed on a FuoroMax®-4 
spectrofluorometer (Horiba Scientific) which allowed direct injection of substrate or 
enzyme into a cuvette for immediate measurement after reactions started. Anisotropy 
values, which indicated the extent of fluorescence polarization, could be read out 
directly and the reactions were monitored by the decrease in anisotropy values with 
excitation wavelength at 490 nm and emission wavelength at 520 nm. The enzymatic 
assays were performed in the reaction buffer (20 mM Tris-HCl, 5 mM DTT, 100 mM 
NaCl, 1 mM EDTA, 0.05% bovine serum albumin, pH 7.5). Buffer and substrate (at 
various concentrations) were predispensed and the reactions were started by adding the 
enzyme, UCH-L3 (ubiquitin C-terminal hydrolase isozyme L3) (human recombinant, 
BostonBiochem, MA). Anisotropy values were collected every 30 seconds. The obtained 
anisotropy values were converted into concentrations of processed substrates [P] with 





[P] is the amount of processed substrates; r0 is the anisotropy of 100% unprocessed 
substrate (determined for each reagent at different substrate concentrations before adding 




anisotropy of 100% processed substrate. Values for initial velocities of individual 
reactions were calculated with Origin 8.5 from OriginLab (Northampton, MA, USA) and 






v is initial velocity; Vmax is maximal velocity (kcat•E); Km is affinity constant; [S] is total 
substrate concentration; E is enzyme concentration. 
Protein ESI-MS Analysis for Fluorescent Ubiquitin Conjugates 
An Agilent (Santa Clara, CA) 1200 capillary HPLC system was interfaced to an 
API QSTAR Pulsar Hybrid QTOF mass spectrometer (Applied Biosystems/MDS Sciex, 
Framingham, MA) equipped with an electrospray ionization (ESI) source. The MS data 
were acquired in positive ion mode (500-2,000 Da) using spray voltage of +2,700 V. 
BioAnalyst software (Applied Biosystems) was used for spectral deconvolution. A mass 
range of m/z 500-2,000 was used for deconvolution and the output range was 8,000-





Results and Discussion 
Firstly, all three Ub-amine conjugates with unique functionalities at the ubiquitin 
C-terminus were labeled with corresponding fluorescein dyes at their respective 
optimized conditions through robust and straightforward click chemistry. The SDS-
analysis of the labeling reactions with w.t.Ub as a control showed the successful 
conversion of all three Ub-amine conjugates to respective fluorescent ubiquitin 
conjugates I-III by comparing the results between Coomassie blue stained SDS gel and 
the fluorescent image of the same gel before Commassie blue staining (Figure 20). 
Furthermore, all ubiquitin-amine conjugates showed nearly quantitative conversion to 
their correspondingly fluorescent ubiquitin conjugates whose detected molecular weights 
by ESI-MS agreed well with their theoretical values (Figure 21-23). The theoretical 








Figure 20. (A) Synthetic route of three Ub-fluorophore conjugates (I, II, III) via 
selective labeling of Ub-amine conjugates (a, b, c) with respective fluorescein dyes (11, 
10, 9). (B) SDS analysis of selective labeling of a-c with fluorescein dyes using w.t.Ub 
as control. The top panel showed the Coomassie blue stained SDS gel and the bottom 






Figure 21. Deconvoluted ESI-MS spectra of Ub-fluorophore conjugates I. The 







Figure 22. Deconvoluted ESI-MS spectra of Ub-fluorophore conjugates II. The 
theoretical molecular weight of II was 9,062 Da. The detected molecular weight of II 






Figure 23. Deconvoluted ESI-MS spectra of Ub-fluorophore conjugates III. The 
theoretical molecular weight of III was 9,062 Da. The detected molecular weight of III 





Since DUB-catalyzed deconjugation reactions of Ub-fluorophore conjugates 
would release small-molecule fluorescein entities that emitted predominantly 
depolarized fluorescence different from their corresponding large-molecule 
Ub-fluorophore conjugates whose emitted fluorescence was much less depolarized, these 
reactions could be easily monitored by following the fluorescence polarization change 
with time. We chose to demonstrate this application of Ub-fluorophore conjugates I-III 
using Ub C-terminal hydrolase isozyme L3 (UCH-L3). When 250 nM I-III were used as 
substrates, increasing UCH-L3 concentrations led to rising rates of fluorescence 
anisotropy decrease at 520 nm emission wavelength (excited at 490 nm) (Figures 24A, 
24C, and 24E). The results indicated that all three Ub-fluorophore conjugates could be 
efficiently cleaved by UCH-L3 in a concentration-dependent manner, validating I-III as 
suitable substrates for UCH-L3. Then we also characterized Michaelis-Menten 
parameters of UCH-L3 with I-III as substrates by performing kinetic studies at different 
substrate concentrations in the presence of 100 pM UCH-L3 (Figures 24B, 24D, and 
24F). The resulting anisotropy change was transformed to the extent of product 
formation as a function of time following the procedure described in experimental 
details part. Initial velocities were then calculated and plotted against substrate 
concentrations. The determined parameters were presented in Table 1 and comparable to 
values reported in the literature for other UCH-L3 substrates such as Ub-AMC,101 
UbR110116 and Ub-Lys-TAMRA.102 These results vindicated I-III as efficient substrates 








Figure 24. Fluorescence polarization assays of UCH-L3 catalyzed deconjugation 
reactions of I-III. (A), (C) and (E) presented reaction time courses of deconjugation 
reactions of 250 nM of I, II and III, respectively, by 0 pM, 50 pM, and 500 pM UCH-L3. 
(B), (D) and (F) presented Michaelis-Menton plots of UCH-L3 catalyzed deconjugation 
reactions of I, II and III, respectively. For (B), (D), and (F), different substrate 








Table 2. Kinetic parameters of UCH-L3 with I-III as substrates.  
Substrate kcat [s-1] Km [nM] kcat/Km [M-1 s-1] 
I 5.8 ± 1.5 492 ± 174 (1.2 ± 0.8) ×107  
II 2.0 ± 0.3 167 ± 53 (1.2 ± 0.5) ×107  






Conclusions and Outlook 
In conclusion, based on our newly-developed one-step approach to modifying 
ubiquitin C-terminus, we employed it with robust click reactions to synthesize three 
types of Ub-based fluorescent substrates for the activity study of DUBs. Their 
applications for DUB kinetic study have been tested with one common DUB-namely, 
UCH-L3 (ubiquitin carboxyl-terminal hydrolase isozyme L3). This facile method is 
suitable for large-scale production of various fluorescent ubiquitin conjugates with 
distinct flexible linkages. The simplicity and high yield of this approach cannot be 
matched by any other current methods. Because research on DUBs, as well as high-
throughput screening for DUB inhibitors hampered by the difficult of producing suitable 
quantities of DUB substrates, this method has the potential to impact several research 
fields. 
Currently, ubiquitin-7-amino-4-methylcoumarin (Ub-AMC) and ubiquitin 
rhodamine110 (UbR110) are two widely used fluorogenic Ub-based substrates for the 
kinetic study of deubiquitinases. Unlike the natural isopeptide linkage in ubiquitinated 
proteins, Ub-AMC and UbR110 have a bulky hydrophobic fluorophore group linked to 
the Ub C-terminus, preventing their hydrolysis by some DUBs. Nevertheless, the Ub-
fluorophore conjugates I-III each contain a linkage between Ub and a fluorophore that 
mimics the native isopeptide linkage of ubiquitinated proteins. Therefore, they are 
expected to be recognized and serve as substrates by most DUBs. 
Furthermore, due to the similarities in both the structures and the conjugation 




described here will provide a method to fluorescently label other Ubl proteins, including 
NEDD8 and SUMO, which will enlarge its application to other research fields as well. 
Altogether, this newly-developed method should greatly facilitate activity studies of 












Ubiquitin (Ub) is a small 76-residue protein modifier27,82 with seven lysines 
which can be conjugated to lysine residues of diverse target proteins to regulate many 
biological processes,24 including protein degradation, signal transduction, embryonic 
development, endocytic trafficking, and the immune response.28,43 Ub can be attached to 
target proteins either as a monomer or as a polyubiquitin (poly-Ub) chain 
(polyubiquitination),23,24 which is diversified by the generation of chains assembled 
through isopeptide/peptide bond between the C-terminal carboxylate group of one Ub 
and any ε-amino group of seven internal Lys residues or the N-terminal amino group of 
another Ub.10,29,33,98,117 This diverse isopeptide/peptide bond formation process produces 
distinct linkage types of linear (homo- and hetero-typic) and branched polyubiquitin 
chains with different topological and cellular characteristics.9,29 Deubiquitinases (DUBs) 
are enzymes that remove Ub from target proteins,15 thus, they regulate most Ub-
dependent cellular processes.12,26 Consistent with this, their misregulation has been 
involved in the pathogenesis of various diseases.38,48,99,100,118,119 Therefore, DUBs, as 
emerging drug targets, have attracted mounting interests from researchers in both 




The human genome encodes more than 100 DUBs.52 To deal with the structural 
complexity of polyubiquitin chains, many DUBs display multiple layers of specificity 
for the recognition of different structural and topological features of diverse 
polyubiquitin chains.28,31,32,120,121 The most striking layer of DUB specificity is the 
ability to select among eight different ubiquitin chain linkages. Besides that, when 
catalyzing the Ub removal, DUBs can potentially remove one Ub at a time from the end 
of polyubiquitin chains (exo-) or cleave within polyubiquitin chains (endo-) to remove 
Ub oligomers or even entire chains from target proteins (Figure 25).67,122-124 Although 
an endo-DUB can theoretically process the Ub removal much more efficient than an exo-
DUB and therefore efficiently balances Ub homeostasis, the endo-hydrolase feature of 
DUBs has been little explored due to the difficult accessibility of polyubiquitin chains 
with structurally defined linkage types. Currently, however, only diubiquitins (di-Ub) 
and several types of homo-typic polyubiquitin (poly-Ub) chain types (Lys11-, Lys48-, 
Lys63-, and Met1-linked) are available for in vitro studies of DUB specificity.15,125,126 
With only limited types of polyubiquitin chains available, the research in the field of 
DUB specificity has been hindered for a long time. Hence the overall picture remains 
incomplete and requires development of new and better reagents and assays to explore 













Several methods including total synthesis and native chemical ligation have been 
applied for the synthesis of different ubiquitin polymers (poly-Ubs).81,84,86,121,127-133 
Pioneered by Ashraf Brik and Chuan-Fa Liu, a mercapto-lysine entity in combination 
with native chemical ligation and desulfurisation has been utilized to synthesize di-Ub 
and poly-Ub molecules for more physiological-based functional studies of particular 
DUBs about their linkage type specificities.84-86,104,134 Alternative poly-Ubs synthetic 
methods which comprised the genetic incorporation of a noncanonical amino acid135-139 
and its following chemical manipulation have also been developed in research groups 
such as Chin, Fushman, Cropp, and Rubini.31,87,121,127,130,140,141 Recently, Strieter and 
coworkers developed a fairly simple method in which a Ub K→C mutant underwent a 
thio-ene photo-click reaction with a Ub-allylamine conjugate for the syntheses of di-Ub 
mimics.  
The isopeptide linkage installation is more or less the most critical step and also a 
major obstacle in the poly-Ubs syntheses.104,142 In order for simple and efficient 
functionalization of the Ub C-terminus with high yields, we invented a facile single-step 
approach to append numerous unique chemical functionalities to Ub C-terminus.89 This 
method was based on E1-catalyzed amidation reaction of the Ub C-terminus. E1 
naturally catalyzes its own thioester linkage formation with Ub (E1-Ub) and 
subsequently transfers Ub to Ub conjugating enzyme (E2) for further Ub transfer. We 
showed that E1-Ub thioester bond could be intercepted efficiently with primary amines 
to form Ub-amine conjugates. One of these primary amines was allylamine. Its 




Ub K→C mutants to afford di-Ub (Ub2) variants with linkages closely analogous to the 
seven native isopeptide linkage types, which was reported by Strieter’s group 
previously.129 The smallest subunits that represent topological complexities of poly-Ubs 
are Ub3 variants.25,26 Therefore, we would like to expand our methodology to synthesize 
structurally defined Ub trimer (Ub3) variants and would like to use them to characterize 
activities (such as endo- and exo- hydrolytic activities) of DUBs. The E1-catalyzed 
amidation reaction could be employed to functionalize the proximal Ub C-terminus of 
Ub2 variants with allylamine molecule to form Ub2-Al that would further undergo the 
thiol-ene photo-click reaction with Ub K→C mutants for the second time to afford Ub3 
variants (Figure 26).20,22 With our developed E1-catalyzed amidation reaction in 
combination with thiol-ene coupling chemistry, we could readily acquire seven types of 
di-Ub (Ub2) mimics and as many as 49 kinds of Ub trimer (Ub3) mimics with mixed 
linkage types. With these versatile ubiquitin polymers as substrates, we could continue 
to study the multiple specificity layers of numerous DUBs. Given its exceptional 
simplicity and universality, our method was expected widely employed in the research 
















The superfamily of OTU DUBs contains 16 members.51,60 They have emerged as 
regulators of important signaling cascades and been implicated in human diseases such 
as inflammation and cancer.59,68,73-75 Recent comprehensive study indicated that most 
OTU DUBs displayed intrinsic isopeptide linkage specificities, preferring one or a small 
subset of isopeptide types.117,143-146 In addition, most OTU DUBs have several Ub-
associating domains that potentially facilitate their binding of several Ub subunits in 
polyubiquitin chains with unique topologies for cleavage of Ub polymers at endo 
sites.71,147 For example, Komander and coworkers showed that OTUD2 could cleave 
K11-, K27-, K29- and K33-linked Ub2 molecules preferentially and displayed a much 
more enhanced hydrolytic activity when a homo-typic K11-linked Ub3 instead of other 
homo-typic Ub3 variants to be used as its substrate. The structure of an inactive OTUD2 
complexed with K11-linked Ub2 also showed that Ub2 was not directly bound at the 
active site.58 Based on these observations, we proposed a mechanism of OTUD2-
catalyed poly-Ubs cleavage shown in Figure 27. A K11-linked Ub2 formed between the 
distal and middle Ubs recruited OTUD2 that rapidly hydrolyzed K11, K27, K29, and 
K33 isopeptide linkages between the middle and proximal Ubs. To examine this model, 
Ub3 variants as shown in Figure 27B that contained the K11 linkage between distal and 
middle Ubs and all other linkage types between middle and proximal Ubs would be used 
as substrates for OTUD2 cleavage specificity study.69 Endo- and exo- DUB activities of 
OTUD2 would lead to different hydrolytic products that could be easily differentiated by 
comparing the size difference (around 1,000 dalton) between wild-type Ub and His-




OTUD2 did have the preference to Lys11 linkage and had the endo-cleavage capability, 
then we would only obtain His-tagged Ub K→C with Lys11-linked di-Ub mimics, while 
if not, its exo-cleavage capability would be evidenced by the presence of the w.t. Ub 
with His-tagged di-Ub mimics.148 Furthermore, different types of second linkage with 
distinct topological features were supposed to affect the efficiency of its cleavage 
activity as well, thereby giving a more comprehensive overview of various interactions 




Figure 27. (A) A proposed linear Ub3 hydrolysis by OTUD2. (B) Potential products of 







Synthesis of lithium acylphosphinate (LAP) 
In a round bottom flask, 2,4,6-trimethylbenzoyl chloride (0.52 mL, 3.2 mmol) 
was added dropwise to a solution of dimethyl phenylphosphonite (0.50 mL, 3.2 mmol) 
in an ice bath. The mixture was then warmed to room temperature and stirred under inert 
atmosphere for 20 hours. The solution of lithium bromide (1.1 g, 12.7 mmol) in 2-
butanone (10 mL) was added to the mixture from the previous step. The mixture was 
heated and stirred at 60°C for 30 min before cooled down to room temperature and left 
stirred for 10 hours. The resulting white suspension was collected by filtration, washed 
with 2-butanone and dried under reduced pressure to give a white powder as the desired 
product (0.94 g, quant.). 1H NMR (D2O, 300 MHz) δ 7.74 (m, 2H), 7.62 (m, 1H), 7.50 






















































































Construction of Plasmids 
Construction of plasmids pETDuet-UbK×C-Histag (× = 6, 11, 27, 29, 33, 48, 63) 
Plasmids pETDuet-UbK×C-Histag (× = 6, 11, 27, 29, 33, 48, 63) were 
constructed from the pETDuet-Ub-Histag by quick change PCR (polymerase chain 
reaction) using respective forward and reverse oligodeoxynucleotide primers for each 
site: 
K6C forward: 5’-TGCACTCTGACTGGTAAGACCATCACTCTC-3’;  
K6C reverse: 5’-CACGAAGATCTGCATATGTATATCTCCTTC-3’;  
K11C forward: 5’-TGCACCATCACTCTCGAAGTGGAGCCGAGT-3’;  
K11C reverse: 5’-ACCAGTCAGAGTCTTCACGAAGATCTGCAT-3’;  
K27C forward: 5’-TGCGCAAAGATCCAAGACAAGGAAGGCATC-3’;  
K27C reverse: 5’-GACATTCTCAATGGTGTCACTCGGCTCCAC-3’;  
K29C forward: 5’-TGCATCCAAGACAAGGAAGGCATCCCTCCT-3’;  
K29C reverse: 5’-TGCCTTGACATTCTCAATGGTGTCACTCGG-3’;  
K33C forward: 5’-TGCGAAG GCATCCCTCCTGACCAGCAGAGG-3’;  
K33C reverse: 5’-GTCTTGGATCTTTGCCTTGACATTCTCAAT-3’;  
K48C forward: 5’-TGCCAGCTGGAAGATGGACGCACCCTGTCT-3’;  
K48C reverse: 5’-CCCAGCAAAGATCAACCTCTGCTGGTCAGG-3’;  




K63C reverse: 5’-CTGGATGTTGTAGTCAGACAGGGTGCGTCC-3’. 
In these plasmids, UbK×C-Histag is under the control of IPTG-inducible T7 promoter.  
Construction of plasmid pETDuet-UbK11C 
The plasmid pETDuet-UbK11C was constructed from the pETDuet-w.t.Ub by 
quick change PCR using forward and reverse oligodeoxynucleotide primers (forward: 
5’-TGCACCATCACTCTCGAAGTGGAGCCGAGT-3’; reverse: 5’-ACCAGTCAGAG 
TCTTCACGAAGATCTGCAT-3’). In this plasmid, UbK11C is under the control of 
IPTG-inducible T7 promoter. 
Protein Expression and Purification 
UbK×C-Histag (× = 6, 11, 27, 29, 33, 48, 63) expression and purification 
To express ubiquitin (Ub) K→C mutants, E. coli BL21 cells were transformed 
with respective pETDuet-UbK×C-Histag (× = 6, 11, 27, 29, 33, 48, 63) plasmids. A 
starter culture was grown in 2×YT media (5 mL) with 100 µg/mL ampicillin at 37°C 
overnight. The culture was inoculated into 2×YT media (200 mL) with the same 
concentration of ampicillin the next morning. Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) (0.5 mM) was added into the cell culture after the OD600 reached 0.9~1.1. The 
cell culture was incubated at 37°C for 8 hours, and the cells were harvested by 
centrifugation at 4,000 r.p.m. for 30 min at 4°C and resuspended in 50 mL of lysis buffer 
(50 mM Tris-HCl, 0.5 mM EDTA, 1 mM DTT, pH 7.5). The resuspended cells were 
sonicated in an ice/water bath four times (4 min each, 10 min interval to cool down the 




centrifugation at 10,000 r.p.m. for 40 min at 4°C. The clarified supernatant was then 
incubated with 5 mL of Ni SepharoseTM 6 Fast Flow beads from GE Healthcare (Little 
Chalfont, United Kingdom) for 20 min for the purpose of effectively binding and then 
poured into a 10-mL empty purification column to allow the Ni sepharose beads to settle 
completely by gravity. The Ni sepharose beads were then washed with 50 mL buffer A 
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 7.8) to get rid of any 
unspecific binding proteins and subsequently eluted out with 12 mL of buffer B (50 mM 
NaH2PO4, 300 mM NaCl, 300 mM imidazole, pH 7.8). The eluted solution was 
concentrated by Amicon Ultra-15 centrifugal filter units - 3,000 NMWL from Millipore 
(Billerica, MA) to 1 mL. The purity of expressed ubiquitin mutants was confirmed by 
SDS-PAGE analysis. The buffer was then changed to 100 mM ammonium acetate (pH 
4.5) by dialysis for further reactions. The concentration was determined by BCA protein 
assay kit from Thermo Fisher Scientific Inc. (Rockford, IL). According to the 
concentration, Ub K→C mutants expression yield were around 150 mg/L from the 2×YT 
media. 
UbK11C expression and purification 
To express UbK11C, E. coli BL21 cells were transformed with pETDuet-
UbK11C plasmid. A starter culture was grown in 2×YT media (5 mL) with 100 µg/mL 
ampicillin at 37°C overnight. The culture was inoculated into 2×YT media (200 mL) 
with the same concentration of ampicillin. Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(0.5 mM) was added into the cell culture after the OD600 reached 0.9~1.1. The cell 




at 4,000 r.p.m. for 30 min at 4°C and resuspended in 50 mL of lysis buffer (50 mM Tris-
HCl, 0.5 mM EDTA, 1 mM DTT, pH 7.5). The resuspended cells were sonicated in an 
ice/water bath four times (4 min each, 10 min interval to cool down the suspension to 
below 10°C before the next run) and the lysate was clarified by centrifugation at 10,000 
r.p.m. for 40 min at 4°C. The clarified supernatant was then acidified by adding glacier 
acetic acid to adjust pH to 3.7 to eliminate the impurities. The purity of expressed 
UbK11C was confirmed by SDS-PAGE analysis. The buffer was then changed to 100 
mM ammonium acetate (pH 4.5) by dialysis for further reactions. The concentration was 
determined by BCA protein assay kit from Thermo Fisher Scientific Inc. (Rockford, IL). 
According to the concentration, Ub K11C expression yield was around 180 mg/L from 
the 2×YT media. 
Syntheses of Ub Dimers by Thio-ene Coupling (TEC) Chemistry 
Reactions contained UbK×C-Histag (Ub K→C mutants) (1 mM), Ub-allylamine 
(Ub-Al) (1 mM), LAP (1 mM) in 100 mM ammonium acetate buffer (pH 4.5) (20 μL 
reaction volume). Samples were placed on ice and irradiated from above with 365 nm 
light for 1 hour using an OmniCure series 1500 light source. Control reactions contained 
w.t.Ub (1 mM) instead of Ub-Al. For UbK11C reaction with Ub-Al, 1 mM UbK11C was 
mixed with 1 mM Ub-Al and 1 mM LAP in 100 mM ammonium acetate buffer (pH 4.5). 
The mixture was placed on ice and irradiated from above with 365 nm light for 1 hour 
using an OmniCure series 1500 light source. The synthesized K11-linked Ub2 was 




Cation Exchange Chromatography for Ub Dimer Purification 
TEC reaction mixture for K11-linked Ub2 was collected and purified by cation 
exchange chromatography with fast protein liquid chromatography (FPLC) system (Bio-
Rad Laboratories, Inc.). The reaction mixture was dialyzed to buffer A (100 mM 
ammonium acetate, 1 mM DTT, pH 4.5) and injected into a 20 mL HiPrep SP HP 16/10 
column (GE Healthcare Life Sciences, Little Chalfont, UK). The program was set as 
followed: 1) the column was washed with a gradient of 0-60% B (100 mM ammonium 
acetate, 1 M NaCl, 1 mM DTT, pH 4.5) over 10 column volumes; 2) then washed with a 
gradient of 60-100% B for one column volume; 3) finally washed with 100% B for one 
column volume. Pure fractions for each peak were collected and concentrated by 
Amicon Ultra-15 centrifugal filter units - 3,000 NMWL from Millipore (Billerica, MA) 
for SDS-PAGE analysis. 
E1-Catalyzed Amidation Reaction for the Syntheses of Ub2-Al (DiUb-allylamine) 
Aliquots of purified mouse E1 stored at -80°C were rapidly thawed and placed on 
ice. The reaction contained 250 µM purified K11-linked Ub2, 20 µM E1, 5 mM ATP, 
750 mM allylamine and was incubated in 1 mL (final volume) of the buffer (10 mM 
CAPS, 250 mM sucrose, 50 mM KCl, 3 mM MgCl2, pH 9.4) at 37°C overnight. The 
conversion rate of the reaction was determined by ESI-MS analysis. The reaction 
mixture was then changed to buffer of 100 mM ammonium acetate (pH 4.5) by dialysis 





Syntheses of Ub trimers by Thio-ene Coupling (TEC) Chemistry 
Reaction mixtures contained UbK×C-Histag (Ub K→C mutants) (2 mM), diUb-
allylamine (Ub2-Al) (0.5 mM), LAP (1 mM) in 100 mM ammonium acetate buffer (pH 
4.5). Samples were placed on ice and irradiated from above with 365 nm light for 1 hour 
using an OmniCure series 1500 light source. The reaction results were further analyzed 
with SDS-PAGE analysis.  
Purification of Ub Trimers from Polyacrylamide Gels 
22 cm (h) × 16.5 cm (w) 12% SDS-PAGE gel was casted and ran by Adjustable 
Slab Gel Kit (C.B.S. Scientific Company, CA, USA). After gel electrophoresis, a clean 
scalpel was used to cut off the region of the protein lane at around 25 kDa according to 
the molecular weight marker lane. The excised gel piece was placed in a clean screw-cap 
culture tube. Then 1 mL of elution buffer (50 mM Tris-HCl, 150 mM NaCl, and 0.1 mM 
EDTA; pH 7.5) was added into the tube so that the gel pieces were completely 
immersed. The gel piece was crushed using a clean pestle and incubated in a rotary 
shaker at 37°C overnight. The next morning, the tube was taken out and centrifuged at 
10,000 × g for 10 minutes. The supernatant was carefully pipetted into a new 
microcentrifuge tube and concentrated using Amicon Ultra-4 centrifugal filter units - 
3,000 NMWL from Millipore (Billerica, MA). An aliquot of the supernatant was tested 





Results and Discussion 
Recently, Streiter and coworkers demonstrated that Ub-Al could undergo a thiol-
ene photo-click reaction with a cysteine-containing Ub mutant to generate a Ub dimer 
mimic. In their method, the synthesis of Ub-Al took advantage of the reversible nature of 
reactions catalysed by yeast ubiquitin C-terminal hydrolase (YUH1), and in the presence 
of YUH1, allylamine was added in large excess relative to a Ub variant harbouring a C-
terminal aspartate cap. Under these conditions, Ub-Al could be obtained in 30% yield.129 
By contrast, our E1-catalyzed amidation approach was more advantageous, providing 
close to quantitative conversion of wild-type Ub to Ub-Al. To test our synthesized Ub-Al 
in the construction of Ub dimer mimics with seven isopeptide linkage types, firstly, 
seven C-terminal Histagged Ub K×C mutants (× = 6, 11, 27, 29, 33, 48, 63) were 
expressed in E. coli and purified by nickel affinity purification (Figure 28). After 
obtaining both purified cysteine-containing Ub mutants and Ub-Al, we further tested the 
thiol-ene photo-click reaction following the Streiter group’s protocol. Equal amounts (1 
mM) of Ub-Al and a Ub KC mutant were mixed in the presence of a photoinitiator, 
lithium acylphosphinate (LAP, 0.5 mM) and placed under UV irritation for 30 min at 
4°C. The formation of a Ub dimer mimic was determined by SDS-PAGE analysis 
(Figure 29). According to the SDS-PAGE analysis, for all seven Ub K×C mutants (× = 
6, 11, 27, 29, 33, 48, 63), corresponding Ub dimer mimics were synthesized with varied 
efficiencies, comparable to what were reported by Streiter et al. Streiter and coworkers 
stated that Ub K27C mutant was refractory toward coupling with Ub-Al, which was not 







Figure 28. Coomassie-stained SDS-PAGE analysis of UbK×C-Histag (× = 6, 11, 27, 29, 
33, 48, 63). UbK×C-histag proteins were expressed in E. coli BL21 cells and purified 









Figure 29. Coomassie-stained SDS-PAGE analysis of thiol-ene photo-click reaction 
products of Ub-allylamine (Ub-Al) with seven 6×Histidine-tagged Ub K×C mutants (Ub 
K→C). Reactions involving w.t.Ub (Ub) served as controls. A weak band with a slightly 
larger size than Ub2 showing in both control and Ub-Al experiments is the disulfide-






With the initial success of the di-Ub mimics syntheses, we further hypothesized 
that Ub dimers with a free C-terminus could be modified using an E1 enzyme as well in 
order to perform the second amidation reaction and afford numerous Ub2-amine 
conjugates, including diUb-allylamine (Ub2-Al). Also, the exo- cleavage activity study 
of OTUD2 required Ub trimers that contained the K11 linkage between distal and 
middle Ubs and all other linkage types between middle and proximal Ubs as substrates. 
Therefore, we constructed and expressed the Ub K11C mutant with a free C-terminus, 
and performed the thiol-ene photo-click reaction with purified Ub K11C and Ub-
allylamine as substrates in the presence of LAP. Since the conversion rate was only 
around 30%, the reaction mixture was then subjected to FPLC (fast protein liquid 
chromatography) purification using a cation exchange column. The K11-linked Ub2 was 
eluted at around 30% buffer B concentration, and its purity was judged by SDS-PAGE 
analysis (Figure 30). 
Based on the universality of E1 enzymes in the ubiquitination system, we 
reasoned that Ub dimers could also be recognized by an E1 enzyme. We therefore 
conducted the E1-catalyzed C-terminal amidation reaction to functionalize the C-
terminus of Ub dimers. With FPLC purified K11-linked Ub2, we tested E1-catalyzed 
amidation reactions following similar conditions with optimized E1 enzyme 
concentrations and determined the conversion rate by ESI-MS analysis (Figure 31). 
Theoretical molecule weights of Ub2 and Ub2-Al were 17,143 and 17,182 Da, 
respectively. According to the ESI-MS results, more than 80% Ub2 was successfully 







Figure 30. (A) FPLC purification chromatogram for the TEC reaction mixture for K11-
linked Ub2. (B) Coomassie-stained SDS-PAGE analysis for each peak observed in the 







Figure 31. Deconvoluted ESI-MS spectra of K11-linked Ub2 after its E1-catalyzed 
amidation with allylamine. Theoretical molecule weights of Ub2 and Ub2-Al were 
17,143 and 17,182 Da, respectively. Detected molecule weights of Ub2 and Ub2-Al were 





Through an E1-catalyzed amidation reaction, alkene functional group could also 
be appended to the C-terminus of Ub dimers, which was supposed to react with a thiol 
group under the conditions of thiol-ene photo-click reaction as well. Therefore, we 
adopted the similar reaction conditions using Ub2-Al and seven C-terminal Histagged 
UbK×C mutants (× = 6, 11, 27, 29, 33, 48, 63) as substrates and conducted a series of 
thiol-ene photo-click reactions to synthesize Ub trimers. The efficiency of these 
reactions was determined by the SDS-PAGE analysis (Figure 32). According to the SDS 
analysis, we found that for all seven positions, respective Ub trimers were successfully 
formed; however, the conversion rate of the thiol-ene coupling reaction was much lower 
than that of using Ub-Al as a substrate. A possible explanation was that, compared to 
Ub-Al, modified Ub2-Al was much more difficult to obtain, considering the loss during 
the first thiol-ene reaction and the FPLC purification, as well as the lower efficiency of 
E1 amidation reaction to the C-terminus of Ub dimers. Thus, a lower concentration of 
Ub2-Al (0.5 mM) was employed to perform the second thiol-ene coupling reaction. 
Although the concentration of UbK×C-Histag mutants was increased to 2 mM, the yield 
was still much lower than the first thiol-ene reaction when 1 mM of both Ub-Al and 
UbK11C were used. Hence, the availability of large amount of purified Ub2-Al was one 
of the key factors for the successful preparation of Ub trimers.  
The low yield of Ub trimers also led to the difficulty in Ub trimer purification. 
We tried cation exchange chromatography following the similar elution conditions as the 
Ub dimers purification. However, mixtures of tri-Ub and mono-Ub always eluted 




high performance liquid chromatography (HPLC) purification with a C4 reverse phase 
column (Phenomenex, USA). After testing numerous purification conditions and 
columns, we decided to extract the protein band directly from the polyacrylamide gel to 
recover the proteins. By following this method, we attempted the purification of seven 
types of Ub trimers with different linkages and subjected them to SDS-PAGE analysis 
for purity determination (Figure 33). Based on the gels, Lys11-, Lys33- and Lys48-
linked Ub trimers were more than 90% pure, while Lys6-, Lys27- and Lys63-linked Ub 
trimers still contained some impurities with similar size as w.t.Ub and di-Ub. For Lys29-





Figure 32. Coomassie-stained SDS-PAGE analysis of thiol-ene photo-click reaction 
products of diUb-allylamine (Ub2-Al) with seven 6×His-tagged Ub K×C mutants (Ub 
K→C). A weak band with a slightly larger size than Ub2-Al is the disulfide-conjugated 









Figure 33. SDS-PAGE analysis of purity of Ub trimers after polyacrylamide gel 
extraction. The position of Ub trimers (Ub3) was marked and (A) - (G) indicated seven 
6×His tagged Ub K×C mutants (× = 6, 11, 27, 29, 33, 48, 63) were used to synthesize Ub 






Conclusions and Outlook 
In summary, we developed a universal and straightforward method to synthesize 
Ub dimers and Ub trimers with distinct linkage types by conducting a E1-catalyzed 
amidation reaction followed by a thiol-ene photo-click reaction. With our newly-
developed E1-catalyzed amidation reaction, we could successfully functionalize the Ub 
C-terminus with allylamine to prepare the Ub-Al conjugate, which was able to react with 
a thiol group in Ub K→C mutants in the presence of photoinitiator lithium 
acylphosphinate (LAP) under UV light. This approach produced all seven linkage types 
of Ub dimers, which can be recognized by diverse families of deubiquitinases including 
USPs, OTUs and JAMMs, according to a previous report by Strieter’s group. Besides 
the syntheses of Ub dimers, we further expanded the combination of these two reactions 
to prepare Ub trimers with desirable linkages in a controllable way, which could further 
serve as versatile substrates for the study of deubiquitinases specificity, including both 
linkage specificity and exo-/endo- cleavage specificity. However, with the extended 
length of the reactants in E1 amidation reaction and thiol-ene reaction, the total reaction 
efficiency was substantially reduced. Moreover, the purification of Ub trimer from its 
respective monomer and dimer also proved to be much more difficult due to the largely-
decreased thiol-ene coupling reaction efficiency. 
Furthermore, beyond the syntheses of Ub dimers and Ub trimers, this method can 
be further adopted as a universal way to prepare Ub polymers with distinct desirable 
linkage types due to its universal applicability. However, owing to its decreased yield for 




especially the development of efficient purification methods for Ub polymers. With 
more advanced purification strategies, this method can be applied to large-scale 
productions of desirable Ub polymers. These distinct Ub polymers can serve as a large 
library that contains various linkage types and topological characteristics for the 
comprehensive study of deubiquitinase specificity, which will provide valuable 





A NOVEL LUMINESCENT ASSAY FOR HIGH-THROUGHPUT SCREENING OF 
DEUBIQUITINASES INHIBITORS AS CANCER THERAPY 
 
Introduction 
Deubiquitinating enzymes (DUBs), also known as deubiquitinases, catalyze the 
removal of attached ubiquitin molecules from lysine residues of target proteins.15 
Deubiquitinating enzymes are a large (106 human enzymes currently, about 20% of all 
human proteases) but catalytically unusual family of proteases, whose physiological 
function is to hydrolyze an isopeptide bond rather than the “classical” peptide bond.102 
The important role of the deubiquitinating enzymes in the regulation of the intracellular 
homeostasis of different proteins and influences in key events such as cell division and 
apoptosis has emerged during the past few years.46 Due to their wide-ranging 
involvement in key pathways such as protein stability regulation, ubiquitin homeostasis, 
and ubiquitin signaling, DUBs might provide new targets for therapeutic interventions of 
various diseases, such as cancer and neurodegeneration.49,70,151-154 For example, ubiquitin 
specific peptidase 2 (USP2), one of the DUB family member, is believed to regulate the 
stability of fatty acid synthase (FAS) in prostate cancer, protect cells from apoptosis and 
interact with mouse double minute 2 homolog (MDM2). USP2 is found to be 
overexpressed in prostate cancer. It deubiquitinates and stabilizes fatty acid synthase 
(FAS), a novel oncogene in prostate cancer and possibly other cancers. Depletion of 




and enhanced apoptosis. 155-157 Therefore, inhibitors of these oncogenic DUB enzymes, 
such as USP2, could lead to enhanced degradation of oncoproteins and may thus stop 
tumor growth.47,48,78-80 
With the increasing interest in DUBs by researchers and the pharmaceutical 
industry, a number of DUB substrates for in vitro analysis are available,34,158-161 many 
relying on naturally occurring DUB substrates such as ubiquitin-60S ribosomal protein 
L40 precursor (ubiquitin-L40) or polyubiquitin chains and designed fusion proteins. 
Cleavage is reflected by a change in molecular weight and is easily monitored by HPLC 
or SDS–PAGE analysis.15 However, this straightforward but laborious assay is not 
suitable for the determination of kinetic parameters of DUBs or high-throughput 
screening (HTS) for DUB inhibitors. HTS of compound libraries against 
pharmacological targets is a key strategy in contemporary drug discovery.46 To generate 
meaningful data with the required throughput, high-quality assay methods are needed for 
translating specific biomolecular phenomena into observable parameters, which is 
achieved primarily through fluorescence and luminescence.162 
In order to derive kinetic parameters of DUBs or perform high-throughput 
screening of small molecule libraries for DUB inhibitors, several fluorescent ubiquitin 
molecules that can serve as DUB substrates have been made available from several 
commercial providers. These DUB substrates rely on the generation or depletion of a 
fluorescent group upon DUB action (Figure 34). The most popular substrate, ubiquitin 
7-amido-4-methylcoumarin (Ub-AMC) is a fusion of the ubiquitin carboxyl terminus to 




mediated cleavage relieves quenching of fluorescence.101 However, Ub-AMC has two 
critical disadvantages when used for drug discovery screening and compound profiling 
campaigns. The major drawback is its unfavorable spectroscopic properties with an 
excitation wavelength (~355 nm) in the UV range, which can excite a significant number 
of screening compounds and thus will generate a large fraction of false positives. 
Another downside of Ub-AMC is that some DUBs fail to cleave the relatively bulky and 
hydrophobic 7-amino-4-methylcoumarin group which is totally different from the Gly-
Lys isopeptide bond found in native ubiquitinated substrates.102,163 
To overcome the shortcomings of Ub-AMC, another fluorogenic substrate, 
rhodamine-based substrate ubiquitin rhodamine110 (UbR110) was designed and 
developed. This substrate is designed to release a monosubstituted rhodamine after 
cleavage by DUBs, which permits the excitation wavelength to be moved to 480 nm, 
reducing the risk of artifacts in screenings due to autofluorescence of compounds.163 
However, UbR110 does not mimic the naturally occurring isopeptide linkage between 
Ub C-terminal carboxylate group and an ε-amino group of a lysine residue of an 
ubiquitinated protein. Recently, fluorescent ubiquitin substrates with native isopeptide 
linkages were synthesized, such as the rhodamine based ubiquitin-εN-(αN-tetramethyl-
rhodamine)-lysine (Ub-Lys-TAMRA). Cleavage of the isopeptide bond resulted in a 
decrease of fluorescence polarization, which made Ub-Lys-TAMRA suitable for high-
throughput screenings.102 However, the moderate dynamic range of fluorescence 
polarization based assay still limits the use of Ub-Lys-TAMRA for compounds profiling 







Figure 34. Scheme of deconjugation reactions of fluorogenic substrates (Ub-AMC and 





Clearly, better model substrates for DUBs inhibitors screening are needed. Based 
on our simple and readily adoptable E1-catalyzed amidation reaction, we synthesized 
ubiquitin-D-cysteine conjugate (Ub-D-Cys) and developed a luminescence-based assay 
for HTS assays of DUBs inhibitors. Compared to fluorescent assays, luminescent assays 
typically show rather low background, which allows for a better signal-to-noise ratio and 
thus higher assay sensitivity.162,164 Bioluminescence is a special form of luminescence 
found in living organisms, which is based on light-emitting enzymes (luciferases) and 
requires specific substrates (luciferins) for light production. The most widely-used 
luminescence assay employs the luciferase enzyme (Luc) from the North American 
firefly, Photinus pyralis. Luc catalyzes the conversion of the natural substrate D-
luciferin, in the presence of oxygen, Mg2+, and ATP, to oxyluciferin in a high-energy 
state. The subsequent relaxation to the ground state yields yellow-green light with a 
spectral maximum of 560 nm.165,166 Our designed luminescence-based assay for HTS 
was based on this natural process (Figure 35). For the Ub-D-Cys, deubiquitinases 
(DUBs) could cleave the amide bond to release the wild-type ubiquitin and free D-
cysteine molecules, while the D-cysteine molecules could subsequently react with 6-
hydroxybenzothiazole-2-carbonitrile to form luciferin, which was reported previously. 
With the presence of ATP, Mg2+, and luciferase enzyme, luminescence should then be 
observed. Therefore, Ub-D-Cys could serve as a novel substrate for luminescence-based 
HTS assays for DUBs inhibitors. We believed that this novel assay would facilitate 
functional investigations of DUBs and accelerated drug discovery for DUB-targeted 







Figure 35. Scheme of designed luminescence-based high-throughput screening (HTS) 
assay for deubiquitinases inhibitors discovery. For the Ub-D-Cys, deubiquitinases 
(DUBs) could cleave the amide bond to release the wild-type ubiquitin and free 
D-cysteine molecules, while the D-cysteine molecules could react with 6-
hydroxybenzothiazole-2-carbonitrile to obtain luciferin. With the presence of ATP, Mg2+, 
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Protein Expression and Purification 
Histidine tagged-ubiquitin specific protease 2 (USP2) 
E. coli BL21 cells were transformed with human USP2 expression plasmid 
(pETDuet-Histag-USP2). A starter culture was grown in 2×YT media (5 mL) with 100 
µg/mL ampicillin at 37°C overnight. The culture was inoculated into 2×YT media (1 L) 
with the same concentration of ampicillin. Isopropyl β-D-1-thiogalactopyranoside (IPTG) 
(0.5 mM) was added into the cell culture after the OD600 reached 0.9~1.1. The cell 
culture was incubated at 37°C for 6 hours, and the cells were harvested by centrifugation 
at 4,000 r.p.m. for 30 min at 4°C and resuspended in 100 mL lysis buffer (10 mM Tris-
HCl, 100 mM NaCl, 10 mM phenylmethylsulfonyl fluoride (PMSF), 2 mM Tris (2-
carboxyethyl) phosphine (TCEP), 1 mM MgCl2, and 100 mg/ml lysozyme, pH 8.0) and 




suspension to below 10°C before the next run) and the lysate was clarified by 
centrifugation at 10,000 r.p.m. for 40 min at 4°C. The clarified supernatant was then 
incubated with 2 mL of Ni SepharoseTM 6 Fast Flow beads from GE Healthcare (Little 
Chalfont, United Kingdom) for 20 min for the purpose of effectively binding and then 
poured into a 10-mL empty purification column to allow the Ni sepharose beads to settle 
completely by gravity. The Ni sepharose beads were then washed with 50 mL buffer A 
(50 mM NaH2PO4, 300 mM NaCl, 10 mM imidazole, pH 7.8) to get rid of any 
unspecific binding proteins and subsequently eluted out with 12 mL of buffer B (50 mM 
NaH2PO4, 300 mM NaCl, 300 mM imidazole, pH 7.8). The eluted solution was 
concentrated by Amicon Ultra-15 centrifugal filter units - 10,000 NMWL from Millipore 
(Billerica, MA) to 1 mL. The purity of expressed USP2 was confirmed by SDS-PAGE 
analysis. The buffer was then changed to the stock buffer (45 mM potassium phosphate, 
300 mM NaCl, pH 6.0) by dialysis. The concentration was determined by BCA protein 
assay kit from Thermo Fisher Scientific Inc. (Rockford, IL). According to the 
concentration, USP2 expression yield was around 50 mg/L from the 2×YT media. 
Purified USP2 protein at 10 mg/mL was divided into small aliquots, frozen in liquid 
nitrogen, and stored at -80°C. 
E1-Catalyzed Amidation Reaction for the Synthesis of Ub-D-Cysteine 
Aliquots of purified mouse E1 stored at -80°C were rapidly thawed and placed on 
ice. The reaction contained 250 µM Ub, 2 µM E1, 2 mM ATP, 5 mM D-cysteine (pre-




mM HEPES, 250 mM sucrose, 50 mM KCl, 3 mM MgCl2, pH 7.4) at 4°C overnight. 
The conversion rate was determined by ESI-MS analysis.  
Cation Exchange Chromatography for Ub-D-Cysteine Purification 
E1 amidation reaction mixture was dialyzed to buffer A (100 mM ammonium 
acetate, 1 mM DTT, pH 4.5) and further purified by cation exchange chromatography 
with fast protein liquid chromatography (FPLC) system (Bio-Rad Laboratories, Inc.). 
The reaction mixture was concentrated to 1 mL and injected into a 20 mL HiPrep SP HP 
16/10 column (GE Healthcare Life Sciences, Little Chalfont, United Kingdom). The 
program was set as followed: 1) the column was washed with a gradient of 0-60% B 
(100 mM ammonium acetate, 1 M NaCl, 1 mM DTT, pH 4.5) over 10 column volumes; 
2) then washed with a gradient of 60-100% B for one column volume; 3) finally washed 
with 100% B for one column volume. Pure fractions for each peak were collected and 
concentrated by Amicon Ultra-15 centrifugal filter units - 3,000 NMWL from Millipore 
(Billerica, MA) for SDS-PAGE analysis. 
Luminescent Assay Procedure for Z-Factor Determination 
With our Biotek® Synergy H1 Multi-Mode Reader (Winooski, VT), the 
LUMITRAC™ 600-384 well plate from Greiner bio-one (Kremsmünster, Austria) was 
used to study the ubiquitin specific peptidase 2 (USP2) cleavage activities to Ub-D-Cys 
based on the designed luminescent assay.  
The reaction buffer consisted of 25 mM Tris, 200 mM glycine, 10 mM MgCl2 




thawed and placed on ice. The stock solutions for each reactant were listed as followed: 
N-ethylmaleimide (NEM, 10 mM in DMSO), 6-hydroxybenzothiazole-2-carbonitrile (1 
mM in DMSO, Sigma-Aldrich), Ub-D-Cys (10 µM in reaction buffer with 5 mM DTT), 
ubiquitin specific peptidase 2 (USP2, 2 µM in reaction buffer with 5 mM DTT), ATP 
(100 mM in water, pH = 7), luciferase from Photinus pyralis (firefly) (1 mg from Sigma-
Aldrich). 
To validate the design of the luminescent assay, Z-factor was determined by 
using N-ethylmaleimide (NEM) as positive control while DMSO as negative control, 





σp is the standard deviations of positive controls; σn is the standard deviations of 
negative controls; µp is the means of positive controls; µn is the means of negative 
controls. 
Firstly, 2 µL DMSO or NEM (10 mM in DMSO) and 20 µL reaction buffer 
containing 150 nM USP2 were added to the LUMITRAC™ 600-384 well plate and 
mixed well. The plate was incubated at room temperature for 20 min. Then 20 µL 
reaction buffer containing 600 nM Ub-D-Cys and 60 µM 6-hydroxybenzothiazole-2-
carbonitrile was added into each well and the plate was incubated at 37°C for 1 hour. 
After that, 20 µL reaction buffer containing 100 µM ATP and 0.2 µg luciferase was 
added to each well and mixed together. Total reaction volume for each well was 62 µL. 




value for Z-factor. Then the Biotek® Synergy H1 Multi-Mode Reader was used to 
determine the luminescence signal for each well. Luminescence fibers were choosen for 
the measurement and the Gain was set at 150, while the integration time was set as every 
one second. 
Luminescent Assay for High-throughput Screening (HTS) 
For the high-throughput screening assay, we used NIH Clinical Collection which 
was a group of 727 compounds with known activity against many cancers to study their 
effects on USP2. The CyBio® Well Vario Channel Simultaneous Pipettor System (Jena, 
Germany) was adopted for automatic pipetting into the LUMITRAC™ 600-384 well 
plate (Greiner bio-one, Kremsmünster, Austria). The Biotek® Synergy H1 Multi-Mode 
Reader (Winooski, VT) which provided detection capabilities in luminescence was 
employed to study the compounds interactions with USP2 based on the designed 
luminescent assay.  
The layout for the 384-well plate was as followed: for the first two columns, 2 
µL DMSO was added manually for each well as the negative controls, while on the other 
hand, 2 µL NEM (10 mM in DMSO) was added manually into the wells in last two 
columns as the positive controls. For those wells between, 2 µL small compounds stock 
solution (1 mM in DMSO) were transferred from NIH Clinical Connection plates into 
each well automatically by the CyBio® Well Vario Channel Simultaneous Pipettor 
System, respectively.  
After that, 20 µL reaction buffer (25 mM Tris, 200 mM glycine, 10 mM MgCl2, 




automatically by the CyBio® Well Vario Channel Simultaneous Pipettor System. The 
plate was incubated at room temperature for 20 min. Then 20 µL reaction buffer 
containing 600 nM Ub-D-Cys and 60 µM 6-hydroxybenzothiazole-2-carbonitrile was 
added into each well and mixed together automatically. The plate was placed into 
incubator at 37°C for 1 hour. Finally, 20 µL reaction buffer containing 100 µM ATP and 
0.2 µg luciferase was added to each well and mixed together automatically. Total 
reaction volume for each well is 62 µL. Then the Biotek® Synergy H1 Multi-Mode 
Reader was used to determine the luminescence signal for each well. Luminescence 
fibers were choosen for the measurement and the Gain was set at 150, while the 





Results and Discussion 
USP2 belongs to the USP family of deubiquitinating enzymes, which is believed 
to inhibit the degradation of various tumor-growth-promoting proteins by removing the 
trigger for degradation. USP2 is thus a promising drug target for cancer therapy. Due to 
its easy-accessibility and relatively high expression levels, we chose USP2 as a target 
and applied our designed luminescent assay for the discovery of USP2 inhibitors. N-
terminal Histidine tagged USP2 was expressed in E.coli BL 21 cells and purified by the 
nickel affinity method. The purity of USP2 was estimated to above 90% by SDS-PAGE 
analysis (Figure 36). 
Using our efficient E1-catalyzed amidation reaction, we functionalized w.t.Ub C-
terminal carboxyl group with a primary amine molecule, D-cysteine, with a near 
quantitative conversion rate, which was indicated by the presence of a peak at 8,668 Da 
from ESI-MS consistent with the predicted molecular weight for a Ub-D-cysteine (Ub-D-
Cys) conjugate (Figure 37). Since our designed luminescent assay was based on the 
reaction between D-cysteine and 6-hydroxybenzothiazole-2-carbonitrile, to remove the 
free D-cysteine molecule in E1 amidation reaction mixture, we conducted additional 
cation exchange chromatography using FPLC to purify the Ub-D-Cys conjugate. Ub-D-
Cys was eluted at around 20% NaCl concentration, as shown in Figure 38. After FPLC 









Figure 36. Coomassie-stained SDS-PAGE analysis of USP2. USP2 was expressed in E. 








Figure 37. Deconvoluted ESI-MS spectra of Ub-D-Cys. The theoretical molecular 









Figure 38. (A) FPLC purification chromatogram for Ub-D-Cys. (B) Coomassie-stained 
SDS-PAGE analysis for each peak observed in the chromatogram: peak 3 contained the 






With purified Ub-D-Cys as the substrate, and purified USP2 as the study target, 
we tested our designed luminescence-based assay with commercially available 6-
hydroxybenzothiazole-2-carbonitrile and luciferase from Photinus pyralis (Sigma-
Aldrich, St. Louis, MO). To validate the applicability of this assay, we employed the 
general irreversible inhibitor of cysteine peptidases, N-ethylmaleimide (NEM), as the 
positive control compared with DMSO as the negative control. 23 parallel assays were 
performed to obtain the value of Z-factor, which was calculated to quantify the 
suitability of an assay for the purpose of high-throughput screening. Firstly, DMSO or 
NEM was incubated with USP2 at room temperature for 20 minutes, respectively, in 
order to interact with the enzyme. Then the substrate Ub-D-Cys was added together with 
6-hydroxybenzothiazole-2-carbonitrile and the reaction mixture was placed at 37°C. The 
USP2 deconjugation reaction was conducted for one hour. During this process, D-
cysteine should be released from the ubiquitin C-terminus and further react with 6-
hydroxybenzothiazole-2-carbonitrile to yield luciferin. The yield of the luciferin was 
dependent on USP2 cleavage activity toward Ub-D-Cys. After one hour, ATP and 
luciferase were added to the reaction system. The resulting luminescence signal was 
measured by the plate reader and a Z-factor value was calculated accordingly. Based on 
the values obtained and listed in Table 3, σp (standard deviations of positive controls), σn 
(standard deviations of negative controls), µp (means of positive controls), and µn (means 
of negative controls) were calculated as 3.9, 487.9, 16.4 and 29.9, respectively. 
Therefore, the value of Z-factor was equal to 0.78, which indicated the excellent 






Table 3. Luminescence value for 23 parallel assays of positive controls (NEM) and 
negative controls (DMSO). 
No. Lum (NEM) Lum (DMSO) No. Lum (NEM) Lum (DMSO) 
1 12 451 13 12 501 
2 19 473 14 19 541 
3 22 471 15 18 464 
4 15 562 16 14 506 
5 18 490 17 12 441 
6 17 501 18 17 484 
7 13 522 19 11 495 
8 15 491 20 14 442 
9 23 461 21 17 495 
10 24 507 22 16 481 
11 12 509 23 23 477 






After initial validation of the assay, we chose to run a test screen with the NIH 
Clinical Collection (NCC), which consists 727 compounds with a history of use in 
human clinical trials. The clinically tested compounds in the NCC were highly drug-like 
with known safety profiles and undiscovered bioactivities for potential therapeutic, 
which could provide excellent starting points for medicinal chemistry optimization and 
might be appropriate for direct human use in treating human disease. Similar procedures 
were adopted for this HTS as employed for the Z-factor determination. Of the 727 
compounds screened, several dozens were found to display inhibitory effects on USP2. 
Among them, several displayed very strong inhibitory effects on USP2 with more than 
ten-fold decreased luminescence signal (Figure 39), and represent excellent candidates 
for further IC50 (half maximal inhibitory concentration) measurement to study their 









Figure 39. The structure of the selected small molecules displaying the highest 
inhibitory effects on USP2 through our developed luminescent HTS assay using Ub-D-






Conclusions and Outlook 
In conclusion, we designed and developed a novel luminescent assay for high-
throughput screening of deubiquitinase inhibitors, and tested it with one common DUB, 
USP2, to validate the applicability of this assay. This innovative assay was built on the 
utilization of E1-catalyzed amidation reaction for the easy preparation of a Ub-D-Cys 
conjugate and the efficient formation of luciferin from D-cysteine to release 
luminescence in the presence of luciferase. The accuracy and suitability of this assay for 
HTS was confirmed by the high Z-factor (0.78). In addition, several small molecules 
from the NIH Clinical Collection were selected for further study due to their relatively 
high inhibitory effects in this assay. 
Compared with currently widely-used fluorogenic ubiquitin conjugates, this 
assay was based on the measurement of luminescence, which resulted in a lower 
background and higher sensitivity. Further, the synthesized DUB substrate, Ub-D-Cys, 
mimicked the native isopeptide linkage compared to currently widely-used substrates-
Ub-AMC and UbR110, and thus should provide a more realistic substrate for the study 
of many other DUBs.  Therefore, this assay could be broadly adopted for DUB inhibitor 
discovery. In addition, the implementation of this assay was straightforward, involving 
simple addition and mixing reagents at different time points, a protocol that could be 
readily adopted by virtually any research group. This substantive departure from the 
status quo was expected to overcome limitations associated with current DUB studies, 
accelerating our understanding of DUB functional roles, and facilitating identification of 




including USP2, USP7, USP9, USP28, etc. With this assay and these oncogenic DUBs 
as drug targets, more small molecules could be screened as potential specific inhibitors 









Post-translational modifications (PTMs) dramatically diversify the proteome. 
Among them, phosphorylation, acetylation, methylation, hydroxylation and 
glycosylation are common types which covalently add respective small chemical groups 
to one or several side chain residues in a protein. Besides, there is another major type of 
PTMs, ubiquitination, which occurs with covalent additions of another protein (ubiquitin) 
to the lysine side chain amino group of a protein substrate. Ubiquitin (Ub) is a small but 
evolutionarily conserved polypeptide with 76 amino acids containing seven lysines (K6, 
K11, K27, K29, K33, K48, and K63) as well as N-terminal amino group, which can act 
as the acceptors for further ubiquitination. Therefore, besides monoubiquitination and 
multi-monoubiquitination defined by the attachment of ubiquitin to one or multiple 
lysine side chain amino groups of substrates, eight types of homo-typic (one linkage type 
per ubiquitin polymer) polyubiquitination as well as various combinations of hetero-
typic (multiple linkage types per ubiquitin polymer) polyubiquitination are also 
indispensable components of the ubiquitination family. The reversed process is achieved 
by deubiquitinases (DUBs), also known as deubiquitinating enzymes. Notably, recent 
studies have revealed that the activities of these enzymes play pivotal roles in numerous 
cellular processes including signal transduction, embryonic development, endocytic 
trafficking, and the immune response. Malfunction of deubiquitinases attributes to 




diseases, thus, DUBs, as an emerging potential drug targets, have attracted increasing 
interests from not only researchers but also the pharmaceutical industry. However, 
currently, the development of DUB research has been largely hampered by the difficulty 
in the accessibility of diversified DUB substrates, including both suitable ubiquitin 
conjugates for high-throughput screening (HTS) assays and various polyubiquitin chains 
for in vitro and in vivo analysis. 
Recently, we developed a novel and facile approach to append numerous 
orthogonal functional groups (thiol, azide, alkyne, alkene, etc.) to the Ub C-terminus 
with high efficiency as well as high yield (>90%) according to electrospray ionization 
mass spectrometry (ESI-MS) by exploiting the catalytic activity of the ubiquitin-
activating enzyme (E1). Beyond this approach, we further developed these 
functionalized Ub derivatives into multiple DUB substrates for the activity study and 
inhibitors discovery of DUBs. Firstly, based on the difference in fluorescence 
polarization, we covalently labelled several functionalized ubiquitin derivatives with 
their respective fluorophores to generate novel fluorescent ubiquitin conjugates and 
adopted them as starting substrates for DUB kinetic study by measuring the fluorescence 
polarization change with reaction time. Besides, inspired by the use of thiol-ene coupling 
reaction for syntheses of Ub dimers described by Strieter’s group, one of the 
functionalized Ub derivatives, Ub-Al, was site-specifically coupled with Ub K→C 
mutants to yield di-Ub mimics. These synthesized di-Ub molecules could be recognized 
by an E1 as well and conducted another E1-catalyzed reaction to produce Ub2-




of Ub trimer molecules. Ideally, this synthetic route might be further applied to longer 
Ub polymers preparation, and these synthesized Ub polymers could constitute a large 
library for the activity and specificity study of DUBs. Furthermore, considering multiple 
types of DUBs acting as oncoproteins, the discovery of their inhibitors would become 
promising cancer therapies. Thus, a novel high-throughput screening (HTS) assay for 
DUB inhibitors discovery was developed on the basis of the bioluminescence process. 
Ub-D-cysteine (Ub-D-Cys) was designed as the starting substrate and produced through 
an E1-catalyzed amidation reaction. The released D-cysteine upon the DUB hydrolytic 
action would cause the production of luminescence after a series of chemical reactions in 
the presence of other substances; thereby the inhibitory effects of different small 
molecules could be readily detected by the luminescence intensity. Altogether, those 
previous chapters were mainly focused on the development and optimization of the E1-
catalyzed amidation reaction and its application in developing novel chemical biology 
tools for investigating deubiquitinating enzymes. 
The initial hypothesis of E1-catalyzed amidation reaction was proposed in 
reference to the pyramidal design of the natural ubiquitination process, E1-E2-E3 
cascade, in which one ubiquitin-activating enzyme (E1) could initiate the concerted 
three-step enzymatic cascade and function together with dozens of ubiquitin conjugating 
enzymes (E2s) and hundreds of ubiquitin ligase enzymes (E3s) to guarantee substrate 
specificities. The universality and high-efficiency of the E1 enzymes to initiate the 
frequent ubiquitination processes in eukaryotic cells inspired us to consider its 




series of primary amines and all of them could be attached to the ubiquitin C-terminus 
carboxylate group with high yields (>90%), which greatly mimicked the natural 
ubiquitination process. For hydrazine, hydroxylamine and cysteamine, due to their 
relatively low pKa and high reactivities, the conjugation of them to Ub C-terminus 
required relatively lower concentrations of small molecules at 50 mM or less, as well as 
physiological pH at around 7.4 at the presence of wild-type ubiquitin, E1 enzyme and 
ATP. On the other hand, for allylamine, propargylamine and azidoethylamine molecules, 
owing to their relatively higher pKa and stability, the attachment of them to Ub C-
terminus had to be conducted under harsher conditions including higher pH at around 
9.4 for their efficient nucleophilic attacks and 10-fold higher concentrations at above 500 
mM. Nevertheless, all of these tested primary amines could be efficiently appended to 
the Ub C-terminus at their respective optimized reaction conditions. Therefore, this E1-
catalyzed amidation reaction provided us an easier approach to functionalize Ub C-
terminus with various functional groups, which could not be achieved previously 
without complicated total chemical synthesis and native chemical ligation. Also, besides 
these reported amine molecules, other primary amines were also supposed to be attached 
to Ub C-terminus efficiently by optimizing their reaction conditions including 
concentrations, pH, etc. In one word, a simple and efficient one-step reaction called E1-
catalyzed amidation reaction was developed by us recently, which could be potentially 
applied for desired Ub C-terminus functionalization. 
Using this straightforward E1-catalyzed amidation reaction, several functional 




aspects. Firstly, we successfully functionalized Ub C-terminus with multiple orthogonal 
groups (thiol, azide, alkyne, etc.), which could be selectively modified to constitute 
different types of Ub-fluorophore conjugates. These Ub-fluorophore conjugates could be 
used as substrates for DUB kinetic study by measuring the time-dependent fluorescence 
polarization change starting from less depolarized large Ub-fluorophore conjugates to 
more depolarized small fluorescein molecules. Among them, the terminal alkyne and 
azide groups could undergo the Cu (I)-catalyzed azide-alkyne Huisgen cycloaddition 
reaction with corresponding clickable dyes at optimized reaction conditions, resulting in 
the generation of desired Ub-fluorophore conjugates with yields above 90%; while the 
thiol group could be efficiently labeled by 5-iodoacetamidofluorescein (5-IAF) and 
achieve a near quantitative conversion to yield a fluorescent ubiquitin derivative with a 
flexible linkage between ubiquitin and fluorophore that greatly mimicked the native 
isopeptide linkage in ubiquitinated proteins. For all three fluorescent ubiquitin 
conjugates, their suitability to serve as DUB substrates was confirmed by testing with 
one common DUB, Ub C-terminal hydrolase isozyme L3 (UCH-L3), and the determined 
kinetic parameters via the fluorescence polarization-based assays were comparable to the 
values previously reported in the literature, which vindicated these three Ub-fluorophore 
conjugates as efficient substrates for DUB activity assays. Compare to currently widely-
used fluorogenic DUB substrates for DUB kinetic study, ubiquitin-7-amino-4-
methylcoumarin (Ub-AMC) and ubiquitin rhodamine110 (UbR110), our newly-
developed three fluorescent ubiquitin conjugates possessed more physiologically-based 




UbR110 contained rather bulky and hydrophobic fluorophores linked to the Ub C-
terminus directly, preventing them from hydrolysis by many DUBs. Besides, the 
synthetic routes of these fluorescent ubiquitin conjugates employed the robust and 
straightforward chemistry for the fluorescent labeling, which rendered them readily 
adoptable for large-scale preparations by a regular biochemistry and molecular biology 
research group. Therefore, these novel fluorescent ubiquitin conjugates were expected to 
become widely-used substrates for DUB kinetic study in future due to their easy-
accessibility and universal-applicability for most DUBs. 
In addition to the application in the field of fluorescent Ub conjugates syntheses 
for DUB kinetic study, the E1-catalyzed amidation reaction could also be exploited for 
Ub polymers (poly-Ub) generation. The one-step high-efficient E1-catalyzed amidation 
reaction was able to attach allylamine to Ub C-terminus, leading to a ubiquitin conjugate 
with the terminal alkene functionality, Ub-allylamine (Ub-Al). Ub-Al was previously 
reported by Strieter’s group that could undergo the thiol-ene coupling (TEC) photo-click 
reaction with Ub K→C mutants as a new approach for the syntheses of Ub dimers. 
Considering the universality of the E1 enzyme in the ubiquitin system, we inferred that 
the E1-catalyzed amidation reaction could also act on a di-Ub molecule to functionalize 
its C-terminus with multiple functional groups through the nucleophilic attack of 
primary amine molecules. Thus, we extended the E1-catalyzed amidation reaction to di-
Ub molecule that was obtained through the thiol-ene photo-click reaction between a Ub-
Al and a Ub K→C mutant, and subsequently functionalized the di-Ub molecule with a 




thiol-ene coupling reaction to generate tri-Ub molecules. Theoretically, E1-catalyzed 
amidation reaction could be applied to any ubiquitin polymer as long as they contained a 
free C-terminus for the nucleophilic attack. Moreover, the thiol-ene coupling reaction 
depended on the concurrent presence of a thiol and an alkene group. Thus, the E1-
catalyzed amidation reaction and the thiol-ene coupling reaction could be combined 
together to serve as a general approach for desired ubiquitin polymer preparation in a 
controllable way. In practice, due to the relatively low reaction efficiency of thiol-ene 
coupling reaction, we had encountered many difficulties in tri-Ub molecules preparation 
and purification, and thus didn’t continue to explore the applicability of this general 
approach for longer Ub polymer preparation. Still, tri-Ub molecules contained the basic 
structure of a Ub polymer, containing a proximal Ub, a middle Ub, and a distal Ub, 
which would be enough for the preliminary exo-/endo- cleavage specificity study of 
DUBs. Besides, there are two linkage positions in tri-Ub molecules, each with seven 
possible linkage types, which would provide abundant materials for the cleavage 
specificity study of DUBs. All in all, a general approach for Ub polymers preparation 
was developed by integrating a E1-catalyzed amidation reaction with a thiol-ene 
coupling reaction, and tri-Ub molecules with desirable linkage types were synthesized 
by following this approach. Current DUB cleavage specificity study was greatly 
hindered by the difficulty in large-scale production of versatile Ub polymers with 
distinct linkage types as well as topological characteristics, and the appearance of this 




preparation and hopefully accelerate the research progress in the field of DUB 
specificity study. 
Besides applying the E1-catalyzed amidation reaction to different types of 
substrates syntheses for DUB activity study, we also broadened its application into the 
field of drug discovery for cancer therapy by developing a novel high-throughput 
screening (HTS) assay. Recent research in DUB field has revealed that many of them 
were overexpressed in various types of cancers and more detailed study uncovered that 
several DUBs, such as USP2, USP7, USP9, etc., acted as oncoproteins in cellular 
pathways. Discovery of specific inhibitors for these oncogenic DUBs could become a 
potential route for future cancer therapy, thus, these oncogenic DUBs have emerged as 
new drug targets in clinical trials. However, in contrast with the increasing attention to 
the drug discovery for these oncogenic DUBs, still, current HTS methods of DUB 
inhibitors had several drawbacks which hindered the progress in the discovery of DUB 
inhibitors. To solve this problem, we developed a novel HTS assay based on 
luminescence detection with the ubiquitin-D-cysteine (Ub-D-Cys) synthesized using E1-
catalyzed amidation reaction as the DUB substrate. After DUB hydrolytic cleavage, D-
cysteine would be released from Ub C-terminus, and it could then react with a 
compound, 6-hydroxybenzothiazole-2-carbonitrile, to generate a luciferin. The luciferin 
would undergo a series of chemical reactions at the presence of ATP, Mg2+, and 
luciferase to release luminescence as the detection signal. The design of this assay was 
especially straightforward and the large-scale preparation of the substrate, Ub-D-Cys, 




Moreover, compared to other current methods, this assay was based on the luminescence 
signal, with much lower background and higher sensitivity than other fluorescence-based 
assays; also, the excited states of luminescence were generated from the luciferase-
catalyzed reaction, which would not intervene with small molecules in the compound 
library, while on the other hand, the production of the excited states in fluorescence was 
gained through the absorption of light, which might also excite a significant number of 
screening compounds to cause pseudo-positive signals. Therefore, this high-performance 
and straightforward assay displayed many advantages over many current methods and 
would be promising to become the general method for DUBs inhibitors screening and 
widely applied to drug discovery field for cancer therapy. 
In conclusion, this dissertation systematically illustrated our recent research 
progress in design and development of novel chemical biology tools for investigating the 
deubiquitinating enzymes, initiating from exploiting the catalytic capacity of the 
ubiquitin-activating enzyme (E1) for ubiquitin C-terminus functionalization, to further 
applying this optimized E1-catalyzed amidation reaction for DUB activity study and 
inhibitors discovery, including the development of preparation methods for desired 
fluorescent ubiquitin conjugates as well as versatile ubiquitin polymers, and 
establishment of a readily-adoptable HTS assay. The most significant merit of our 
approach was its exceptional simplicity and broad applicability for the large-scale 
syntheses of multiple substrates for DUB research by a regular biochemistry and 
molecular biology group that was either not equipped or not capable to handle organic 




dramatically facilitate functional investigations of DUBs as well as accelerate drug 
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